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ABSTRACT 
 
Modern cancer immunotherapy involves the conditioning of endogenous T cells to 
fight cancerous bodies that have managed to resist or avoid detection. Recently 
approved antibody drugs target the immune checkpoint pathway in T cells to 
prevent their tolerance to cancer antigens. There exists a compelling need, 
especially in the drug discovery world, to develop better assays for screening and to 
study the underlying mechanisms of these new antibody drugs. 
 The core motivation of my work is to develop a primary cell assay for the 
immune checkpoint pathway using 1-D imaging cytometry. The assay is focused on 
high throughput and high content screening. It takes advantage of our novel 1-D 
imaging cytometer platform. The assay is designed to artificially induce anergy in 
primary human T cells and systemically study their drug response. An automated 
statistical method quantifies the functional phenotypes of both healthy and anergic 
T cells into a single descriptive readout. Reducing localization of biomarkers into a 
single ‘activity score’ readout has many advantages for drug screening and 
characterization. Additional assays were developed to study T cell activation 
  vii 
dynamics and other signaling events during the immune checkpoint pathway. 
 Our 1-D instrument leverages both the high throughput aspects of traditional 
flow cytometry and the high spatial content of 2-D imaging cytometers. The PMC 
data analysis emphasizes an unbiased approach to analyze flow cytometry data, 
which eliminates the subjective manual gating of current cytometric methods. This 
is crucial to developing more accurate and reliable assays with minimal supervision 
and need for expert operators. The high-throughput and high-content capabilities 
presented enable new types of assays previously not possible with human primary 
T cells. Adoption of physiological relevant primary cell assays has potential to 
revolutionize large-scale drug screening and future applications in personalized 
medicine. 
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Chapter 1 - Introduction 
1.1 Problem statement 
Cancer immunotherapy is one of the fastest-growing areas in cancer research. Much 
of the recent drug development has been focused specifically on the immune 
checkpoint pathway (Intlekofer & Thompson 2013; Marincola et al. 2003; Prieto et 
al. 2012; Robert et al. 2014). Therefore, there exists a need to develop more specific 
and efficient screening assays to study drug interactions on this pathway. High 
content assays are well suited for studying the immune checkpoint pathway as they 
provide intracellular information even with relatively small T cells (Starkuviene & 
Pepperkok 2007; Zanella et al. 2010; Singh et al. 2014). High throughput is needed 
in addition to high content to provide the statistical strength that is required for 
drug discovery screening. Statistical significance and automation becomes even 
more important when dealing with primary cells with high biological variance 
(Eglen & Reisine 2011). 
 The current technologies to study T cells have traditionally been limited to 
single-stream non-imaging flow cytometers. Traditional flow cytometers are 
unparalleled in cell throughput. Most modern flow cytometers can measure 
thousands of cells per second with up to 32 separate colors per cell (Edwards & 
Sklar 2015). However, these measurements do not yield any spatial information for 
their corresponding biomarkers. They also traditionally have low well throughput. 
Similar to non-imaging flow cytometers, the 2-D imaging approach has its own 
limitations with regards to throughput and cell type. Plate readers can only image 
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single wells one at a time which limits sample-to-sample turnover. At high 
magnifications, images may contain low cell counts that limit statistical power. Most 
2-D imaging cytometers are strictly limited to adherent cells, and the one 
commercial 2-D imaging cytometer has very limited well throughput (Millipore 
2017). 
1.1.1 Hypothesis 
As a result of the limitations of traditional flow and 2-D imaging cytometry, we 
chose to develop high content imaging in flow. Our main objective is to develop a 
new type of 1-D imaging methodology that is optimized for the study of antibody 
therapeutics. 
The goal of this work is to design and optimize the parallel microfluidic 1-D 
cytometer (PMC) platform. We argue that this new approach is highly suited for 
studying dynamic T cell pathways at high throughput in flow. Its particular strength 
is quantitatively higher well throughput than has been previously possible for flow 
imaging. These advantages stem from parallel fluidics and statistical data analysis. 
We use statistical thresholding and regression modeling to build an automated 
pipeline that streamlines the entire process of data reduction.  
The secondary goal of this work is to use the new 1-D imaging system to 
develop a novel assay to probe drug response in immuno-compromised T cells. 
Immune checkpoint drugs reverse and prevent tolerance of a patient’s endogenous 
T cells against existing cancer antigens. To study the efficacy of these drugs, one 
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needs an assay that can probe compromised T cells in a systematic way. In addition, 
using primary human T cells increases the physiological relevance in measuring the 
drug response. Primary human T cells are rarely used in drug screening applications 
because of the many research challenges they pose, the least of which, is that most 
assays consume large volumes of cell sample, rendering them impractical for 
primary human cells. Our application has the advantage of requiring minimal 
volumes and cell numbers, allowing thousands of conditions to be probed from a 
single clinical sample.  
 
 1.2 Aims 
1.2.1 Aim 1 - Optimize PMC instrumentation 
The parallel microfluidic cytometer (PMC) collects 1-D fluorescence images from 
individual cells at high speeds. The main purpose of this aim was to advance the 
engineering development of this instrument design. This requires optimization of 
the optical/electronic components and high throughput sample collection. The 
current PMC design uses a galvanometer to scan a focused laser. It provides high 
imaging speeds but at the same time has many trade-offs with regards to spectral 
overlap, signal to noise, sensitivity, and unwanted variance across lanes. The 
microfluidics and operating protocols were optimized for better throughput and 
reproducibility. 
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1.2.2 Aim 2 - Design statistical framework for 1-D image analysis 
High content screening (HCS) involves measuring large numbers of cell images and 
converting them into a simple readout. Correlating 1-D images from our optical 
system to their 2-D analogues was one of the goals of this work. Validation with 
traditional 2-D microscopy was used to confirm drug responses. One of the biggest 
challenges in HCS is the large amount of data that is generated from each cell. The 
main goal of this aim was to develop an automated streamlined statistical workflow 
to reduce multi-dimensional imaging data into a single drug response activity score 
by means of regression modeling. The single readout score is a reduced measure of 
how well a drug performs. Finally, it is important to have high sensitivity for any 
assay, so much of the work was maintaining high separation between positive and 
negative controls.  
1.2.3 Aim 3 – Develop immunotherapy assay based on functional T cell response 
The last aim was to develop an assay to measure the anergy and recovery of primary 
human T cells. The general approach involved inducing an anergic state in purified 
human T cells and then adding various drug candidates to measure the resulting 
response. Drugs that are successful in preventing or recovering cells from anergy 
should return the cells to a more responsive state. We decided to use T cell 
activation and nuclear translocation of NFAT to measure this functional state. 
Before the final assay was constructed in full, many of the individual components of 
the assay were tested first in a cell line. 
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Although there are other ways to measure anergy (such as surface markers 
or cytokines), measuring the functional state of internal signaling pathways is more 
useful in studying the exact mechanisms of action. Immune checkpoint blockade 
drugs inhibit many signaling pathways related to T cell activation. In addition, drugs 
can have unwanted or nonspecific effects that can affect multiple signaling networks 
within a cell. 
Many of our methods are adapted from 2-D HCS, so we conducted additional 
validation assays to compare our approach with existing HCS. Dose response, drug 
inhibition, and kinetic curves were generated. Also, we show the high throughput 
capabilities of our technology by scaling up to a 96-well plate. 
 
1.3 Structure of thesis 
In summary, this work involves development of a platform to study the mechanisms 
and efficacy of T cell immunotherapy. Chapter 2 introduces all the relevant 
background information regarding current flow cytometry approaches, T cell 
signaling pathways, and current immunotherapy approaches. Chapter 3 introduces 
the full design of the PMC. It covers the development of the instrumentation and 
fabrication methods for the PMC hardware. Testing and validation are shown in 
appropriate sections. Chapter 4 presents the full statistical pipeline and its 
development. Chapter 5 presents the anergy assay and the preliminary steps 
building up to the final design. Multiple translocation pathways were tested in a 
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Jurkat cell line.  Chapter 6 concludes the major findings of the work and discusses 
future directions. 
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Chapter 2 - Background 
2.1 Flow cytometry 
2.1.1 Traditional flow cytometry 
Flow cytometry (FCM) has been used for decades in the measurement of surface and 
intracellular antigens (Shapiro 2003). Qualitative and quantitative differences are 
measured to characterize cellular function and differentiation. Applications include, 
but are not limited to, immuno-phenotyping, cell sorting, rare cell detection, small 
particle analysis, signaling pathway analysis, kinetics, and DNA/RNA measurement 
(Shapiro 2003). Some of the most common commercial systems are the BD Accuri, 
BD LSRFortessa, BD FACSAria, Miltenyi MACSQuant, Thermo Fisher Attune. Cell 
sorting is also available in many flow cytometer instruments, and is based primarily 
on charge droplet or magnetic droplet separation (Richardson et al. 2015). This is a 
relatively simple task in single stream flow cytometers, as the stream can be 
diverted when a specified fluorescence threshold is detected.  
A classical flow cytometer involves a single cell suspension flow channel, 
which is illuminated by a fixed laser. Emitted fluorescence is collected via an optical 
path that filters out unwanted laser wavelengths, while preserving the relevant 
emission wavelengths. Photomultiplier tubes (PMTs) are usually used to collect the 
emitted fluorescence. A simplified diagram is shown in Figure 2-1. 
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Figure 2-1. Diagram of single stream flow cytometer. 
A single stream cell suspension is brought into contact with a fixed laser, 
typically an Argon-Ion laser. The labeled cells are excited and emitted 
fluorescence is collected by a series of photodiodes (scattering) and 
photomultiplier tubes (PMTs). Dichroic mirrors serve as bandpass filters to 
isolate each color into its corresponding PMT. Collection optics are varied but 
typically involve telescoping and objective lenses to focus the emission path 
onto the PMT cathodes.  Image taken from (Brown & Wittwer 2000).  
 
The setup of a traditional single stream flow cytometer is highly serialized yet 
extremely efficient at analyzing single cell suspensions. A typical system is capable 
of analyzing cells at speeds of 10,000 cells/s with low coefficient-of-variance (CV) 
and high sensitivity. Single cell suspensions are hydrodynamically focused with 
sheath fluid for accurate alignment with the excitation laser beam. The cytometer in 
Figure 2-1 has 4 color channels (one for each PMT) and a single argon-ion laser. 
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However, many commercial cytometers have multiple lasers and up to 32 color 
channels. 
Flow cytometers are typically limited to suspension cells. Although adherent 
cells can be detached from growth vessels or de-aggregated, there is a penalty that 
the detachment process can cleave surface proteins and affect internal biology. FCM 
is unparalleled in its cell throughput, but in turn, is limited in sample throughput. A 
single stream input requires samples to be scanned one at a time, so the sample 
throughput is limited by how fast the loading apparatus can be cycled. Some 
companies have attempted to overcome this limitation by using a pulsatile pump to 
deliver an ‘air gap delimited stream’ (Intellicyt iQue Screener Plus) with a fast 
robotic handler. This particular system claims a sampling throughput of 96 wells in 
5 min. 
One of the fundamental limitations to FCM is that the laser spot is designed to 
be much larger than a cell, thereby foregoing intracellular information. Each cell is 
labeled with multiple fluorescent labels, which can produce up to 32 separate data 
points per cell. However, each fluorescent data point is an indication of the summed 
fluorescent coming from the cell. This can be regarded as a zero-dimensional (0-D) 
image/point. Cell assays are designed accordingly to this spatial limitation. There is 
another practical constraint, particularly if too many fluorescent labels are used. 
Crosstalk and interference can result from spectral overlap of fluorophore emission 
profiles (Roederer 2001). Compensation and spectral demixing is a required step in 
many protocols. 
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For data analysis, histograms and scatter plots are used to differentiate 
individual populations and quantify changes. A highly trained operator will gate 
populations by manually drawing boundaries around the relevant populations. An 
example of this process is shown in Figure 2-2.
 
Figure 2-2. Example of flow cytometry panel: scatter plots for differentiating perivascular 
cell populations. 
An example of the typical scattering plot approach for gating subpopulat ions to 
differentiate cells. Cells are labeled with two separate surface markers and 
plotted against one another. Populations are gated (indicated with red boxes) 
by manually drawing thresholds around cells using expert operators. (Crisan et 
al. 2008) 
 
An important aspect of this gating process is the use of manually drawn boundaries. 
Automated data clustering algorithms do exist but they are not reliable or practical 
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(Abraham et al. 2014). To fully separate subpopulations usually requires three 
standard deviations (SD) of separation for reliable analysis. If the subpopulations 
are noisy or too closely overlapping, an operator must make a qualitative and 
subjective judgement to determine the correct gating boundaries. For complete and 
unbiased gating, each subpopulation must have an identifying subset of surface 
markers and/or must be as dissimilar from each other to make a determination. 
2.1.2 Imaging cytometry 
Another approach, that adds 2-D intracellular marker localization, is termed 
imaging cytometry. Compared to FCM, the underlying concept is the same, however, 
instead of a single stream flow channel, most imaging cytometers use microtiter 
plates and CCD cameras or laser scanning microscopes to image the cells. Imaging 
cytometry that is related to drug discovery and high throughput methods is called 
high-content analysis (HCA) (Freeley et al. 2010). Similar to FCM, HCA uses a wide 
range of fluorescence excitation and emission detectors for multiplexed cytometry. 
Common imaging cytometers on the market include BioTek Cytation, Thermo Fisher 
ArrayScan, and the PerkinElmer Operetta. The instrumentation varies across 
imaging platforms. One of the greatest advantages of HCA is that 2-D images can 
provide information on the intracellular localization of biomarkers. Assays include 
signaling transduction pathways, co-localization, cell-cell interactions, live cell 
kinetics, morphology/cytoskeleton tracking, spot counting, and many more (Singh 
et al. 2014). 
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Most HCA systems are confined to use with adherent cell cultures. Although 
not completely impossible, in practice, suspension cells floating in wells are nearly 
incompatible with a fixed focal plane imaging system. Well throughput of HCA 
systems is also limited. Throughput depends on multiple factors such seeding 
density of the cells and robotic systems. The cell and sample throughput are 
typically much slower than FCM, but can be improved with robotic handling and 
automated systems. Many modern HCA systems can analyze a 96-well plate in 5–10 
min. High NA objectives and magnifications are often used and adjusted for 
diffraction limited imaging for submicron resolution. Due to the complex 
autofocusing and robotic handling, HCA contains additional imaging artifacts that 
are not present in FCM. Artifacts such as high background noise from improper 
washing, cell debris, overlapping cells, overexposure, and inconsistent illumination 
are common. (Bray et al. 2012; Bray & Carpenter 2004). Temporal artifacts and edge 
effects are also problems, as wells are imaged serially.  
2-D images allow for statistical study of spatial and temporal processes 
within cell populations (Shariff et al. 2010). Images are first “segmented” to isolate 
each cellular compartment from the image of the full well. Features, mathematical 
constructs used to analyze cell images, are calculated from each cell. HCA maximizes 
information content by measuring hundreds to thousands of features for each 
labeled biomarker. These features are quantitative measures of cellular features 
ranging from texture, area, perimeter, morphology, frequency coefficients, cell-cell 
adjacency, and more (Singh et al. 2014). Thousands of features can be generated 
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from each cell and a typical well may contain hundreds of cells. Thus, HCA is 
naturally suited for statistical algorithms as a means to process the data. Phenotypic 
changes can involve very subtle changes. Without the separate identifiable tags for 
each marker, algorithms are used to determine the most statistically significant 
features for population discrimination. These include algorithms adapted from the 
world of machine learning, classifiers, supervised/unsupervised learning, clustering, 
and regression modeling to select the most important features (Kozak et al. 2009; 
Kümmel et al. 2011). For screening applications, a list of a thousand features can be 
reduced to a single feature depending on the assay. Overall, the general approach of 
HCA is to reduce highly-dimensional data sets into easily interpretable readouts. 
2.1.3 Combination cytometry (imaging & flow) 
Due to the success of FCM in the areas of immunology, there has been a recent 
resurgence in the development of imaging methods that incorporate flow. Imaging 
flow cytometry (IFC) has the advantage of high content spatial resolution of 2-D 
imaging. Some current imaging flow instruments include the EMD Millipore 
ImageStream®X Mark II (Zuba-Surma et al. 2007), multi-field-of-view IFC 
(Schonbrun et al. 2012), temporal coded excitation (Gorthi et al. 2013), STEAM 
(Goda et al. 2009), FIRE (Diebold et al. 2013), and others (Han et al. 2016). 
  
14 
 
Figure 2-3. Diagram of ImageStream®X imaging cytometer. 
One of the only commercial available imaging flow cytometers on the market. A 
synchronized optical integrator combined with a spectral dichroic filter stack 
projected onto a CCD array allows 2-D imaging in flow. Image taken from 
(Zuba-Surma et al.  2007). 
 
Only the first instrument (EMD Millipore ImageStream®X Mark II) is currently 
commercially available (Figure 2-3). It uses a sensitive time-delay integrator that 
applies synchronized imaging of cells in a single stream flow channel. The images 
obtained from the ImageStream®X are high resolution but its throughput is limited 
by its strict flow stability requirements, CCD detector speed, and serial operation. 
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Since cells are in flow, as opposed to static conditions in 2-D imaging wells, there is a 
fundamental limitation in acquisition time, noise, and sensitivity. Many of the 
previous technologies attempt to solve this issue in different ways. For example, one 
method, STEAM, converts spectral information into the time domain to achieve 
higher sensitivity with extreme speeds. Another method FIRE uses radio frequency 
waves to modulate the light excitation for simultaneously fluorescence imaging. 
 Despite these improvements in imaging flow cytometry (IFC), there is still a 
fundamental bottleneck with the data analysis (Giuliano et al. 2003). Similar to HCA, 
imaging in flow generates an enormous amount of data per cell. The challenges of 
acquiring, storing, processing massive numbers of cell images is a persistent 
problem in IFC. However, the silver lining for IFC is that some imaging difficulties 
with 2-D HCA can be avoided in flow. Segmentation algorithms such as threshold, 
watershed and edge detection are computationally expensive but is completely 
unnecessary in flow.  
2.1.4 Microfluidic cytometry 
The field of microfluidics is readily compatible with the concepts of cytometry, as 
both aim to manipulate small particles in single or multi stream pathways for 
imaging analysis (Godin et al. 2008). One of the biggest advantages of microfluidic 
devices is the ease of adding additional functionality into a compact device. Switches 
and sorting modalities can easily be introduced. Most commonly, laminar flow is 
present, with low Reynolds numbers. Microfabrication is highly scalable; devices 
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made in polydimethylsiloxane (PDMS) or plastic can be reproduced quickly and 
cheaply. Figure 2-4 presents some current prototypes of cytometry devices that 
have been built as microfluidics. One of the biggest advantages of microfluidics is 
that new lane geometries can be exploited, such as parallel flow. However, imaging 
in flow with microfluidics has many challenges. Surfaces can present scattering and 
reflection losses. Detection of weak fluorophores and scattering is difficult in these 
devices, due to typically higher backgrounds.  
         
Figure 2-4. Examples of microfluidic technologies used for cytometry. 
A) Fully integrated cytometer into a single fluidic chip. Optical wave guides and 
pump inlets and outlets are multiplexed into a compact system. B) Examples of 
optical wave guides to focus laser paths into small fluidic channels. C) Example 
of flow geometries for hydrodynamic focusing and buffer systems.  Images 
taken from (Godin et al. 2008). 
 
A B 
C 
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2.2 T cell immunology 
2.2.1 Introduction 
T cells are lymphocytes that mature mainly in the thymus. They compose a large 
part of the adaptive immune system and include cytotoxic CD8 cells, helper CD4 
cells, memory and regulatory T cells (Yamanaka et al. 2013). The main difference is 
that helper T cells bind to MHC II (related to extracellular pathogens) and cytotoxic 
T cells bind to MHC I (related to intracellular pathogens/damage). Binding of the 
MHC complex from antigen presenting cells to the T cell receptor (TCR) triggers an 
activation cascade that eventually leads to clonal proliferation/recruitment of B 
cells and macrophages. This eventually results in the creation of antigen specific 
antibodies and subsequent release of cytokines to destroy foreign or self-antigens. 
Self-antigen recognition is particularly important to prevent auto-immune diseases 
and cancer (Anderson et al. 1999). 
2.2.2 T cell activation 
When a naïve T cell encounters an antigen presenting cell (APC), the TCR binds to 
the corresponding antigenic epitope and MHC complex (Smith-Garvin 2009). Each 
TCR has a highly variable region which is specific to one ligand. The TCR will then 
communicate with a CD3 complex that becomes non-covalently bonded to the TCR. 
The TCR is then referred to as the TCR:CD3 complex. The CD3 receptor contains an 
immuno-receptor tyrosine-based activation motif (ITAM) region on its cytoplasmic 
tail. In vitro, it is possible to bypass the requirement of TCR ligation and directly 
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bind to the CD3 component to simulate MHC interaction. Costimulatory receptors, 
such as CD28, can enhance the activation response (Figure 2-5). Directly following 
litigation of the TCR complex, the remaining TCR complexes on the cell surface will 
begin to aggregate and localize in a super cluster, a phenomenon known as capping 
(Kammer et al. 1983; Schreiner & Unanue 2011). The aggregation of TCR complexes 
is a rapid event that begins seconds after binding of the TCR. Maximal capping, 
where more than half the cells receptors are aggregated, occurs in around 10–15 
min (Kammer et al. 1983). 
After the immunological synapse is established, various signaling pathways 
are triggered as shown in Figure 2-6 (Ilani et al. 2007). Protein tyrosine kinases 
(PTK), Lck and Fyn are activated by CD4/CD8, CD28 and CD45. These help 
phosphorylate ITAM on CD3. This leads to recruitment of ZAP-70 and further 
signaling cascades. PLCγ and DAG dependent pathways are activated. These result 
in the activation of two major pathways, Ras and PKCƟ, which are involved in the 
translocation of transcription factors including Extracellular Signal Regulated 
Kinase (ERK), c-Jun N-terminal Kinase (JNK), Nuclear Factor-KappaB (NF-kB) and 
Nuclear Factor of Activated T-Cells (NFAT).  
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Figure 2-5. Immune synapse of a CD8+ T cell. 
Surface receptor organization during T cell activation and ligation. TCR is the 
main receptor that recognizes MHC complexes on antigen -presenting cells.  
CD28/CD8/CD2 are co-stimulatory receptors that enhance the immune 
response. Image taken from (https://med.nyu.edu/skirball-
lab/stokeslab/tcell.html). 
 
2.2.3 NF-kB/NFAT translocation 
The transcription factors NF-kB and NFAT are both critical components in T cell 
proliferation (Srivastava et al. 2010; Baine et al. 2009). They both require significant 
translocation to the nuclear compartment to activate their corresponding genes. The 
NF-kB factor is bound to an IkB inhibitor at rest. After activation, IKK 
phosphorylates IkB which then allows the NF-kB to translocate into the nucleus and 
activate gene expression as a transcription factor. For NFAT translocation, after TCR 
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activation there is an increase in cytosolic Ca2+. This activates calcineurin which 
then dephosphorylates pNFAT. An alternate method to trigger calcium release is 
with small molecules PMA and Ionomycin. This allows NFAT to translocate into the 
nucleus and form complexes with other transcription factors. The destination for 
many of these pathways is increased secretion of IL-2, IL-2 receptors (CD25), CD69 
(cell surface proliferation glycoproteins) and eventually proliferation. These two 
pathways are notable, and useful for cellular imaging assays since they involve 
spatial localization of a biomarker.
 
Figure 2-6. Signaling transduction network of T cell activation. 
Left hand side shows the normal activation pathw ay and translocation of 
relevant transcription factors. The immune checkpoint pathway is displayed on 
the right. Binding of PD-1 triggers a cascade that results in T cell inhibition, 
tolerance and anergy.  Image taken from (Okazaki et al.  2013). 
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2.2.4 Immune checkpoint blockade 
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 
protein 1 (PD-1) are receptors involved in the T cell checkpoint blockade pathway 
(Parry et al. 2005). These receptors appear much later and peak around 24–48 
hours after initial activation (Nirschl & Drake 2013). Both receptors contribute to 
help regulate self-tolerance and autoimmunity (Intlekofer & Thompson 2013). In 
this work, we focus solely on the PD-1 pathway for multiple reasons. It has been 
discovered that many cancer types have shown to express large amounts of PD-L1 
to avoid detection by the immune system (Iwai et al. 2002; Andorsky et al. 2011). 
PD-1 targeting drugs have also shown less side effects than CTLA-4 targeting drugs 
in clinical trials (Hamid et al. 2013). Both Keytruda (Powles et al. 2014) and Opdivo 
(Robert et al. 2014) are PD-1 antagonistic antibody drugs (also known as immune 
checkpoint blockade) that have been recently approved by the FDA. They have 
shown great potential for use in melanoma treatment and are underlying phase III 
clinical trials.  
When PD-L1 (PD-L1 is the ligand to PD-1, also known as B7-H1) binds to PD-
1, SHP2 is recruited and dephosphorylates PI3K (Hapter et al. 2003). This inhibits 
AKT activation, as well as ZAP70, PLCγ, and CD3 related events, all of which are 
crucial in T cell activation and proliferation. Both NFAT and NF-kB translocation 
occur downstream of those signaling events. Therefore, it is safe to assume that both 
NFAT and NF-kB translocation will be compromised as a result of PD-1 activation. A 
summary of the PD-1 pathway is shown in Figure 2-6. Immune checkpoint blockade 
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drugs (ex. Keytruda, Opdivo) are proposed to work by blocking the binding of PD-1 
ligands to PD-1 receptors, thereby preventing immune tolerance. 
 
2.3 Cell models 
2.3.1 Jurkat 
Jurkat (E6.1 clone) is an immortalized lymphoblastic cell line that was extracted 
from an acute T cell leukemia patient (Abraham & Weiss 2004). Jurkat cells are 
known for their ability to produce IL-2 after TCR activation. Jurkats have been used 
extensively to characterize the events involved in TCR signaling pathway, therefore 
we chose them for the T cell activation studies in this work (Abraham & Weiss 
2004). However, there are several limitations of Jurkats. They have large nuclei 
which makes it difficult to differentiate between cytoplasmic and nuclear 
compartments. Also, Jurkats are immature lymphoblasts which lack CD4 and CD8 
expression. Jurkats also have abnormal PTEN and SHIP phosphatases, the effect on 
activation is still unknown (Abraham & Weiss 2004). Jurkats are immortal cell lines 
so they cannot be stopped from proliferating or entering anergy (our results 
confirm that attempting to stop the cell cycle or activating the PD-1 pathway results 
in apoptosis). Despite the downsides, Jurkats are useful due to their TCR kinetics, 
homogeneity, and ease of culture in vitro. 
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2.3.2 Primary cells 
 
Clinical trials are the required standard for drug testing. Obviously due to practical 
and safety reasons, experimental drugs such as immune checkpoint blockade cannot 
be tested at early stages, in vivo, in humans. Before clinical trials can be conducted, 
specialized cell lines or animal models are typically used to test and screen for drugs 
(Hughes et al. 2011). Since most drugs being developed have human targets, 
maintaining physiological relevance is an important factor when choosing a model. 
Most of our assays are initially tested in Jurkat cells for the practical reasons above, 
but transitioning into primary cells is the end goal, as it will allow for better 
prediction of true immune responses. 
Primary cells obtained from peripheral mononuclear cells (PBMCs) from 
patients have high physiological relevance but also many difficulties in assays 
(Longo et al. 2012). For example, assays that involve reporter genes can be difficult 
in primary cells (X. Huang et al. 2017). Transfection using viral methods can cause 
unwanted immune responses. Also, there is a huge amount of heterogeneity and 
biological variance between patient PBMC samples. Primary cells obtained from 
human donors cannot be fully characterized down to every single genomic mutation 
or alteration. There is always the danger of working with contaminated cell 
populations, but antibiotics can reduce the risk. 
Using primary cells for drug studies has many potential benefits (Eglen & 
Reisine 2011). Some drugs are only effective on certain people with specific genetic 
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defects. For example, Keytruda (Pembrolizumab, anti-PD-1 blockade drug 
developed by Merck) has been shown to be extra effective on patients with the 
mismatch repair genetic defect (Skora et al. 2015). Pre-screening is a natural step 
for many clinical trials and personalized medicine to determine individual drug 
response (Robert et al. 2014). Weekly or monthly check-ups using cytometric 
analysis on blood samples is common during clinical trials (Red blood cell count, 
white blood cell count, leukemia panels, CD4/CD8 expression). The methods that 
will be presented in this work can be easily adapted into existing clinical trial 
methods. It has been discovered recently that certain tumor states can be reflected 
in peripheral T cells (Ki67) (A. C. Huang et al. 2017). Although, used sparsely 
because of practical difficulties, primary peripheral immune cells can provide 
multiple advantages in both clinical and drug discovery applications. 
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Chapter 3 – Aim 1 – PMC Instrumentation 
3.1 Overview 
The PMC is a single axis confocal scanning laser microscope that obtains 1-D 
fluorescence scans of cells (Cheung et al. 2015; McKenna et al. 2011; Mckenna et al. 
2009). The system combines the high cell throughput of flow cytometry with the 
intracellular localization of imaging cytometry, and the parallelism of microfluidics. 
The philosophy behind this instrument is to re-allocate detection bandwidth, by 
compromising on image dimensionality and resolution, to obtain higher throughput 
for drug screening applications. It has been shown previously that the information 
stored in low-pixel-count 1-D images is sufficient to differentiate between cellular 
phenotypes such as nuclear accumulation of NF-kB in Chinese hamster ovary (CHO) 
cells and many other validated assays (McKenna et al. 2011). The parallel flow 
geometry allows much higher sample throughput, the current microfluidic uses 16 
parallel fluidic lanes. The random sampling of the PMC provides high statistical 
power even with low hit rates. 
3.1.1 Design 
The instrument we designed is based on a scanning laser detector with a traditional 
galvanometer scanner (Cambridge Technology H6240H). Figure 3-1 provides an 
overall diagram of the PMC system. 
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Figure 3-1. Diagram of PMC system. 
The PMC resembles a typical confocal imaging setup but with one axis removed. 
A single argon-ion laser is used for excitation. Telescoping lens (A) and 50mm 
focal length objective focuses the laser to the parallel microfluidic chip. The 
galvo scans in a single axis across parallel  fluidic lanes in the chip. Emitted 
fluorescence is collected into a PMT box with dichroic bandpass filters for each 
color. An optional pinhole (B) eliminates out of focus light.  Image from (Wang 
& Ehrlich 2017).   
 
A 
B 
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A single-line 488-nm Argon ion laser is focused to a nominal 2-µm diameter spot 
through a 50-mm focal length, 0.35-numerical-aperture mesoscopic objective. 
Similar to a confocal microscope but with one axis removed, a galvanometer scans 
the laser across the parallel lanes of the microfluidic chip. The scanning frequency of 
the galvanometer mirror is 12.5 scans/s. 1-D images are acquired simultaneously on 
1-4 photomultipliers (Hamamatsu H957-8) with one PMT reserved for scatter light. 
Images are digitized using a 14-bit analog-to-digital converter (ADC, Vertilon 
ISQP518, Vertilon Inc., Westfield, MA). The sampling rate is 60 kHz. Emission filters 
for each photomultiplier tube 660±25 nm (red channel), 570±10 nm (orange 
channel), 525±20 nm (green channel) and 488±5 nm (scatter detector).  
The first prototype designed outside of this work used a rotating servomotor 
instead of the scanning galvanometer outlined in Figure 3-1 (McKenna et al. 2011). 
This first generation PMC system provided a proof-of-concept for 1-D imaging 
cytometry. The second generation system that was built for this work featured a 
scanning galvanometer and was fully integrated to include automated fluidics and 
robotic pipetting. A picture of this first iteration is provided in Figure 3-2 (right) and 
the full documentation in Appendix 1. Unfortunately, it was overly complicated to 
operate and unnecessary for low-throughput assay development. A second iteration 
(still using the scanning galvanometer) was built to accommodate easier workflow 
and faster customization. This was the primary system used for all the assays 
presented and an image is provided in Figure 3-2 (left).  
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Figure 3-2. Real life images of 2nd generation PMC prototypes. 
Left) Primary PMC system. The black metal casing protects the inteneral optics. 
The objective is directly underneath the microfluidic chip and scans from left 
to right across the parallal lanes. Power supplies and the ADC are connected 
externally along with a high processing computer to analyze the data collected.  
Right) Initial PMC build with fully automated fluidics and robotic pipettor. This 
first iteration was built to accomadate high throughput capablities and was 
designed as a complete integrated all-in-one system.  
 
3.1.2 Comparisons to current cytometry approaches 
The PMC obtains localization information of fluorescent markers in suspension cells 
as mentioned in Chapter 2.1.3. However, our instrument is unique in its use of 1-D 
imaging instead of more standard 2-D imaging. We chose this lower-pixel-count 1-D 
imaging approach in order to obtain higher sample throughput, particularly when 
combined with parallel microfluidics. For our assay development and needs, we 
built a system with 4 PMT color channels. Theoretically, the PMC system can be 
designed with the same multicolor multi-laser optical complexity as in traditional 
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FCM. In general, classical cytometers require highly trained operators to analyze the 
complex data sets (Kümmel et al. 2011). An important part of our work has been to 
create an automated workflow (Chapter 4) to eliminate subjective data reduction. 
Overlapping and out-of-focus cells are common imaging artifacts in 2-D 
imaging assays. Cells can easily detach during pipetting and/or plate perturbations. 
Suspension cells are problematic since they float at variable heights in the wells. 
Centrifuging solves some of these issues, but is ultimately sensitive to vibrations or 
movement since suspension cells are non-adherent. Out-of-focus images are only 
partially addressed through power log-log slope (PLLS) histograms, and other post 
processing methods in classical 2-D cytometry (Bray et al. 2012). In contrast, the 
PMC uses a scanning confocal detector which has out-of-focus rejection built 
directly into the hardware and software. A pinhole, or equivalent software, is used 
to eliminate out of focus light. In software, this is done through thresholding and 
automated gating. Once the focus is calibrated, it is stable for an entire day. This 
avoids additional hysteresis or focusing errors from constant dynamic focusing. 
Edge effects are another source of well-to-well artifacts in 2-D HCS. These 
can be minimized through complex plate models, reference plates, longer incubation 
times, or removing edge wells altogether (Bray et al. 2012). Equivalent effects exist 
in the PMC in the form of spatial non-uniformity across the fluidic lanes. This is 
managed through individual calibration of each flow lane and selecting careful 
controls. As for temporal drift effects, the PMC avoids them as all lanes are scanned 
simultaneously. 
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Image segmentation (boundary determination of cell compartments and cell-
to-cell separation), is another well-known source of error during reduction of 2-D 
HCS data. Most segmentation algorithms assume even illumination, high contrast of 
cytoplasmic/nuclear boundaries, and physically non-overlapping cells (Shariff et al. 
2010). For adherent cells that are touching or overlapping, more complicated 
algorithms are needed such as Voronoi segmentation. Even if everything is ideal, 
best-fit estimations, kernel filters, clustering, and/or predetermined masking are 
still needed to achieve optimal segmentation with some amount of noise injected 
nonetheless. The PMC requires no segmentation step since the nuclear 
compartment is indicated by a nuclear counterstain. We accept a full line-scan for 
each color channel and extract features without segmentation or boundary 
definition. 
One of the biggest advantages of using 1-D imaging is that all the data 
analysis is intensity-normalized as opposed to classical flow cytometry. Our features 
are insensitive to any overall differences in fluorescence intensity or PMT gain. 
Normalized features are not dependent on overall intensity and are highly tolerant 
to variability in sample preparation and artifacts from staining, oversaturation, or 
contrast. 
Data efficiency is an important aspect of 1-D imaging. For a typical 10 µm cell, 
our system only needs 20 pixels per color to extract all the necessary information at 
1 µm resolution (McKenna et al. 2011). In comparison, a 2-D system at 0.5 µm 
resolution would require a minimum of 400 pixels for the same image. 1-D imaging 
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is at least an order of magnitude more data efficient than 2-D imaging. This is 
especially important to many users, who complain of the data storage requirements 
of 2-D HCA systems. Furthermore, data efficiency is an important aspect of real time 
data analysis and sorting applications enabled by our sparse 1-D imaging approach. 
 
3.2 Instrumentation 
This section will cover the various experiments that were conducted to improve on 
the instrumentation and hardware of our new cytometer. 
3.2.1 Optics 
It was determined empirically that 25 nm wide dichroic filters were the optimal 
balance between signal-to-noise (SNR) and spectral overlap with our relatively 
modest laser. Polyclonal secondary antibodies were essential to achieve maximum 
SNR and sensitivity. The main fluorophores used our assays were Alexa 488 and 
propidium iodide, which naturally have low spectral overlap (Figure 3-3). A third 
color was attempted but a sufficiently high enough quantum yield fluorophore was 
not found. CF594 was the closest one tested with an ex/em of 488nm/594nm, but 
the sensitivity was too low to be detected in the PMC. 
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Figure 3-3. Graph of emission wavelengths in the PMC. 
All fluorophores and excited by a 488nm Argon-Ion laser. Alexa 488 emits at 
around 530nm. The green shaded rectangle indicates the bandpass wavelengths 
for the dichroic emission filter for Alexa 488, around 520nm. The red shaded 
rectangle indicates the bandpass wavelengths for the emission filter for 
propidium iodide (PI). Since PI has a much broader emission curve, a bandpass 
filter near 670nm was chosen.  Image is created using BD Fluorescence Viewer 
(http://www.bdbiosciences.com/us/s/spectrumviewer ).  
 
Intensity independence was studied intensively. Each 1-D image is first normalized 
by subtracting the noise floor background and dividing by the peak intensity of the 
1-D curve. As mentioned above, this normalization makes feature metrics resistant 
to common imaging artifacts present in 2-D imaging (dye aggregation, improper 
detector settings, debris contamination, and local evaporation). To test the intensity 
independence of our algorithms, we simulated poor staining protocols by varying 
the PMT gain of our instrument across an order of magnitude as shown in Figure 3-
4. Feature distributions are converted into Z-scores and displayed as a heatmap. 
Features that deviate from the original population are indicated by the color 
mapping (more red). 
  
33 
 
Figure 3-4. Heatmap showing normalized and unnormalized features vs. PMT gain. 
Green values represent a positive difference from the mean. Red represents a 
negative difference from the mean. Eight parallel lanes are imaged 
simultaneously with 8 separate reductions in PMT gain from 10x down to 1x 
(relative gain). Each column is an individual lane. The gap betw een columns 
represents the separate gain reductions and experimental conditions. Each row 
is an individual feature but is grouped into general clusters as listed on the 
right. Image from (Wang & Ehrlich 2017). 
 
As expected, the raw (intensity dependent) features scale directly with PMT gain. 
Decreasing the gain of fluorescent intensity (from left to right) should result in 
decreased values for intensity-dependent features. Raw peak intensity, width, area, 
and perimeter all show significant shifts in feature distributions as indicated by the 
heatmap. Intensity independence is also confirmed, as normalized features show 
minimal change when PMT gain is varied across an order of magnitude. Although 
  
34 
there are small differences between parallel lanes, the maximum deviation from the 
mean across all normalized features is ±10%. 
To address the spatial lane-to-lane variance of the optical system, mainly due 
to field aberrations in the optics, we collected data using uniform 2.5-µm-diameter 
fluorescent polystyrene beads (Invitrogen Align Flow #A7302) (Figure 3-5). Beads 
are suspended at 2 million beads/mL density and flowed through 14 parallel lanes 
in the microfluidic chip. Fluorescent excitation is captured by the PMC and features 
are calculated based on each individual scan described in Chapter 4. Selected 
features are plotted and show in Figure 3-5 for analysis of variance across all 14 
lanes.
 
Figure 3-5. Lane variance across parallel lanes using new galvo scanning optics. 
Features plotted for 2.5-µm-diameter fluorescent polystyrene beads. Beads are 
imaged across 14 parallel fluidic lanes. A) Raw feature calculations across 
entire 4mm scanning region. Means in each lane have a typical U shape profile. 
X-position represents the axis parallel to the laser scanning path which scans 
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periodically across parallel fluidic lanes. B) Normalized feature that uses a 
ratio between widths. Much less variance. C) Peak intensity across lanes shows 
that features are largely independent of intensity. D) Representative 1 -D 
images taken from 3 extreme locations within the chip. The difference in shape 
show an average profile of each lane.  Image from (Wang & Ehrlich 2017). 
 
For unnormalized intensity dependent feature (FWHM), the coefficient-of-variance 
(CV) was 19% for edge lanes and 7% for center lanes (Figure 3-5A). The maximum 
deviation from the mean was +8% for edge lanes and -6% for center lanes.  This 
showed the initial problems that we had with spatial variance across lanes. These 
features are a sensitive measure of the laser beam shape factors at the focal plane. In 
Figure 3-5B, we analyzed a normalized feature summarized as the 25/75 ratio. This 
feature is the log of the full width at 75% peak divided by the full width at 25% peak 
for a single cell event and normalized to a control sample of the same beads. The 
variance for the 25/75 ratio feature is much lower than the previous unnormalized 
feature. To test if our variance was a function of laser power, we also looked at peak 
intensity vs. X-position (Figure 5-3C). Peak intensity measures the maximum signal 
peak from each unnormalized 1-D image. This feature is equivalent to the single 
point measurement obtained from FCM. The variance in peak intensity did not show 
any correlation with feature variance. However, peak intensity can be used to 
measure the slight tilt along the scanning axis and an asymmetric loss of 
fluorescence strength. Finally, representative 1-D image scans from the left, center, 
and right fluidic lanes are shown in Figure 3-5D. Each profile is a cumulative 
average peak intensity of all beads within a single lane. The shape of the bead 
profiles can serve as useful diagnostics of the optical alignment and residual optical 
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aberrations in the hardware.  
Despite the imperfections in alignment and optical design, accurate scoring is 
preserved through normalization algorithms. Figure 3-5B shows how typical feature 
variance is compensated with our algorithms. An alternate method to reduce this 
variance is to separate each lane into its own separate data analysis. While this 
removes lane-to-lane variance, it also removes inter-lane comparisons and reduces 
the well throughput. Another method to reduce spatial edge effects would be to use 
professional machining methods to perfectly align all the lenses and internal optical 
components. 
3.2.2 Scattering 
Side scatter and forward scatter are common channels in many cytometry panels. 
Scattering information is useful for measuring size and shape/complexity factors of 
cells. One common assay uses strictly scattering channels to determine multiple 
subpopulations of T cells (Figure 3-6). Forward scatter indicates size differences 
and side scatter indicates internal shape complexity (Nicholson et al. 1996). 
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Figure 3-6. Side scatter vs. Forward scatter of T cells. 
Clusters of different T cell types are identifie d without any receptor labeling.  
High internal complexity is detected using side scatter while overall size is 
detected using forward scatter.  Subpopulations such as monocytes, 
lymphocytes, and granulocytes can be identified by their corresponding side 
scatter to forward scatter ratios. Both axes are relative strengths of scattering 
intensity. Image taken from Principles and Applications of Flow Cytometry 
(Roger S. Riley n.d.)  
 
Many attempts were made to incorporate a fiber optic cable to pick up side scatter. 
Methods included micro-machining internal channels inside the poly(methyl 
methacrylate) PMMA microfluidic chip, using solvents to smooth out internal 
surfaces, testing various angles to place the fiber optic (direct back scatter to 90˚), 
and trying different core sizes. We discovered that a constant noise floor was 
produced in our scattering detector by surface roughness and reflections in the 
microfluidic. 
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Figure 3-7. Scattering experiments using plastic beads and fiber optic cable. 
A) Scattering data obtained from PMMA chip results. Left-hand plot shows the 
collected 488nm backscatter light  using the scattering PMT channel . Each row 
is a separate scan with the laser. The x-axis represents the position of the laser 
(4 mm total width). The fiber optic cable is placed underneath the chip at a 45 ˚ 
angle. Right hand plot shows the fluorescent PMT channel  (Alexa 488) to detect 
the presence of a cell. B) Methods are replicated using a glass chip.  Left is 
scattering PMT channel. Right is corresponding fluorescent PMT channel  (Alexa 
488). 
 
One can see on the lefthand side of Figure 3-7A that the scattering signal from the 
PMMA chip was barely observable above the noise floor. When the PMMA chip was 
replaced by a glass etched version, the signal-to-noise (SNR) was much higher 
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(Figure 3-7B). These results confirm observations from the literature. The 
microfabrication and molding processes that we use lead to micro-defects and 
roughness in the fluidic walls (Diaz-Quijada et al. 2007; Wang et al. 2011). These 
caused high optical and electronic noise (PMT gain was near 100%), and resulted in 
unusable SNR. 
3.2.3 Electronics 
It was determined empirically that a 60 kHz sampling rate at 12.5 scans/s resulted 
in a nominal 1 µm resolution. The 1 µm spatial resolution was selected because 
previous studies indicated that enough information was preserved at this resolution 
(McKenna et al. 2011). To verify the resolution, the sampling rate was adjusted in 
the ADC until the pixel width matched 150 pixels for each fluidic lane, each of which 
is 150 µm wide. Another factor to consider was the integration time of each pixel. To 
maximize sensitivity and SNR, 17 µs integration time was measured to be a good 
compromise between speed and signal intensity, for our specific laser power 
wattage. The Argon-Ion laser has a maximum power output of 50 mW. 
Other improvements in the electronics involved the incorporation of custom 
conditioning circuits to modulate the galvanometer (Appendix 2). This required a 
combination of high-pass and low-pass filters and integrators using op-amps. A 
custom Arduino circuit was built to control the PMTs automatically using serial 
input/output (Appendix 3). Minor electrical components were added to minimize 
electronic interference (shielded cables, grounding capacitors, etc.). 
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3.2.4 Microfluidics 
The microfluidic chip was fabricated using standard photolithography, 
electroplating, and polymer embossing into a final poly (methyl methacrylate) 
(PMMA) mold. The dimensions of each channel measured 150 µm x 40 µm (Figure 
3-9). Each fluidic lane was separated by a 150 µm wall. The chip material PMMA was 
chosen for multiple practical reasons. PMMA is easier to machine input and output 
wells and can be imprinted quickly using a single master embossing mold. The 
sealing tape method is replaceable which simplifies cleaning and makes each chip 
reusable. Compared to laser etched fusion bonded glass chips in the previous 
iteration, the process is simpler, more scalable, and cost effective. A summary of the 
microfabrication process is shown in Figure 3-8. 
  
  
41 
 
Figure 3-8. Microfabrication overview for the microfluidic chip. 
Masks with flow channel geometry were generated in AutoCAD and printed 
with high quality photomask ink (Output City). A tree geometry was selected 
over a ladder geometry for negative pressures because of better resistance 
distribution under steady state (V. Hessel, A., Renken, J.C. Schouten 2009) . 
Silicon wafers (University Wafers, 150 mm SSP Si) were dehydrated at 115 ˚C 
for 5 min on a hot plate. Then wafers were spin coated with HDMS at 3000 rpm 
for 30s. Positive photoresist (Shipley Micro posit S1818) was spun at 2000rpm 
for 3 µm thickness. Wafers were pre-baked at 120˚C for 120s. Wafers are 
exposed in a mask aligner (Karl Suss MA6) at 200mJ. Wafers are then 
developed in photoresist developer solution (MF319) and rinsed with  DI and 
post-baked for 5 min at 120˚C. Deep reactive ion etching (DRIE)  was used to 
etch each wafer to a depth of 50 µm (Bosch process SF6 etch at 7.5s with C4F8 
passivation 3.5sec for 60 cycles). We then deposited 500 µm of titanium using a 
CHA evaporator as seeding layer for electroplating. Wafers were electroplated 
to a thickness of 700 µm with nickel to create  master mold (NiCoForm).  
 
The embossing protocol was adapted from similar embossing techniques in the 
literature (Chen et al. 2010; Shen et al. 2002; Mathur et al. 2009; Tsao & DeVoe 
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2008; Narasimhan & Papautsky 2004). Plates were heated to 150˚F and 290˚F. The 
master mold was aligned with a pre-etched PMMA chip and silicone rubber (1/4” 
McMaster-Carr 8632K44) sandwich into embossing machine (Carver Model 3912). 
The mold sandwich was preheated for 10 min, then applied with 900 kPa for 2 min. 
After cooling for 2 hours under pressure, chips were sealed with silicone adhesive 
TempPlate RT Optical film (USA Scientific #2921-7800). A 0.25/20 threaded fluidic 
adapter and 1/16” diameter polyethylene tubing was attached to the vacuum output 
port. The chip layout is shown in Figure 3-9. 
 
Figure 3-9. Microfluidic chip layout as seen from above. 
Samples are loaded into 16 input wells at the bottom and flowed through the 
chip using negative vacuum pressure (-0.10 PSI). A magnification of the 
detection zone is on the right which shows the perpendicular laser scanning to 
the flow direction.  Cells flow through the parallel fluidic lanes in the laminar 
flow regime. The laser intersects the cells at random cross sections.  
 
  
43 
One of the interesting results learned from the microfabrication process was during 
the embossing development. Since the input and output wells were pre-drilled into 
the PMMA and then embossed, we needed to maintain the integrity of the wells, but 
at the same time, maintain a solid imprint of the mold. Traditional hot embossing is 
always done with a solid blank chip first, and then holes are cut. Due to the reverse 
method, we had to carefully adjust the temperature gradients and pressure to 
determine the optimal conditions for the reverse embossing method. This method 
may be a new approach to microfluidic embossing since we could not find any 
literature on this method. It has advantages over the standard method since the 
reverse embossing technique allows the input wells to maintain structural integrity. 
Machining input wells into plastic can often destroy small features in microfluidic 
chips. The structural integrity and shape of the lanes was confirmed with a manual 
profilometer (data not shown).  
 Other chip iterations were planned but only partially completed. One of those 
iterations was a 96-well lane chip. By using 50 µm wide lanes, we could fit 96 wells 
into a 10 mm scanning region. This would allow for even higher throughput 
screening but we did not have the time or resources to implement it (Appendix 4). 
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3.3 PMC Operation 
3.3.1 Cell preparation 
We developed a standardized protocol for sample preparation. This protocol was 
used with little variation for all the experiments that follow. 
Cells are fixed by adding 10 µl of 37% formalin (Sigma #F8775) for 15 min 
on ice, and then permeabilized with 0.1% Triton X-100 for 10 min. Cells are 
centrifuged, aspirated, and re-suspended in our custom flow/staining buffer, which 
consists of 1% BSA (bovine serum albumin) and 10 mM EDTA in PBS (phosphate 
buffered solution). Appropriate primary antibody is added and incubated overnight 
at 4˚C. Cells are washed and re-suspended in flow buffer. For the secondary staining, 
10 µg/mL of anti-rabbit Alexa 488 (Invitrogen #A11008), 1:100 propidium iodide, 
and 10 µg/mL of RNase A are added and incubated for 30 min at 37˚C. Cells are 
washed twice and fixed a second time for 3 min. After one final wash, cells are 
filtered with a 40 µm mesh and re-suspended at a density of 2 x 106 cells/mL in flow 
buffer with 30% OptiPrep.  
All the above protocols were optimized over a course of 7 years. Each 
concentration and incubation time of every compound was fully titrated to 
determine the optimal point. For the staining, fixing, and permeablization protocols, 
the time intervals and concentrations were chosen to achieve the maximal nuclear 
fluorescence of the antibody staining but also minimal cell clumping and 
deterioration of the membranes. Paraformaldehyde was tested to be inferior to 
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freshly prepared fixing buffers with 37% formalin. Triton X-100 was determined to 
be better at permeablization than saponin, which is another common detergent. The 
flow buffer was carefully constructed to reduce the sticking of ions and DNA and cell 
debris. The concentration of OptiPrep was carefully titrated, too high would reduce 
flow rates, but too low would increase cell settling and clogging. Concentrations for 
all antibodies were titrated for maximal fluorescence at saturation. Higher 
concentrations also allow for lower incubation times, which is crucial for high-
throughput processing.  
3.3.2 Cell processing 
Before imaging cells in the PMC, samples are stored temporarily at room 
temperature in a closed box to prevent photobleaching. Cells are then manually 
loaded into the wells using a pipettor. Each lane was loaded with 4 µl of sample 
volume at a cell density of 2 million cells/mL, roughly 8,000 cells per well.  
When using primary cells, sample volume efficiency is especially important 
as cells are limited in quantity from a single donor. The PMC has very low volume 
requirements of 4 µl per well. A 96-well plate typically has a working volume of 50-
200 µl per well. Even for a 384-well plate, each well usually requires an optimal 
working volume of 15–150 µl. In our protocols, 50–150 million purified CD3+ T cells 
were obtained from each individual donor. Even considering 50% cell loss from 
staining and washing, there are still 25–75 million usable cells, sufficient for 3000–
9000 separate wells.  
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After loading, cells were siphoned through the chip at -0.10 PSI vacuum 
pressure. After each run, wells were flushed with 1% detergent for 1 min. At the 
beginning of each day, the PMC was focused to the optimal Z-axis position. Optimal 
focus was confirmed by measuring the FWHM (full width half max feature) and peak 
intensity at various Z-axis positions. Figure 3-10 shows the data from 9 different Z-
axis positions. It was confirmed that the optimal focal point existed where the 
FWHM was at a minimum and the peak intensity was at a maximum. 
 
 
Figure 3-10. Plot of FWHM and Peak intensity vs. Z axis position. 
FWHM and Peak amplitude feature means plotted for beads as a function of 
vertical Z position. The blue curve shows the mean FWHM value in pixels of 
beads at a certain Z position. The lowest FWHM feature is around a Z position 
of 12. The green curve shows the mean peak intensity  feature of beads vs Z 
position. The lowest amplitude is also around 12. Vertical bars represent 
standard deviation across 10 replicates.  
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3.3.3 Flow modeling  
Some work was necessary to get consistent low velocity flow within the microfluidic 
chip. Negative pressure is more susceptible to inconsistencies in flow, especially 
with parallel lanes (Yi et al. 2006; V. Hessel, A., Renken, J.C. Schouten 2009). The 
microfluidic chip was modeled to identify improvements and to calibrate the flow 
parameters to maintain consistent flow and minimize flow rates for optimal sample 
imaging. Resistance in a rectangular channel can be estimated using 
(12*η*L)/(w*h3), where w is width, h is height, η is viscosity of the fluid (0.001 
pa*s), L is the length of the lane. Resistances are added in parallel to determine 
overall flow rate and velocity. Based on the density of the fluid (1100 kg/m3) and 
the velocity, length, and viscosity of the fluid, the flow regimen should be completely 
laminar in our chip, based on Reynolds number, and confirmed with empirical 
observation. The model was used to predict flow rates as a function of pressure. 
Actual flow rates were measured using particle tracking and the results are 
compared with the theoretical model in Figure 3-11. To measure actual flow rate, a 
camera was placed above the microfluidic lanes and opaque beads were flowed 
through the chip. Using the frames/second as a reference, the velocities of each 
individual bead could be tracked and calculated (Appendix 5-6). 
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Figure 3-11. Laminar flow model calculated from resistance of microfluidic chip. 
Velocity and flow rate measurements obtained from both empirical data a nd 
theoretical model. Red indicates the velocity calculated from the theoretical 
flow resistance model. Green triangles are mean values from experimental bead 
tracking data. Increasing the negative pressure results in higher flow rates and 
velocities. There is a direct linear relationship between pressure and velocity 
as expected from the theoretical model.  
 
3.3.4 Flow issues 
Sample handling protocols required extensive optimization to maintain smooth 
operation of the PMC. For example, we discovered that double fixing cells with 
formaldehyde is crucial to eliminating sticking of the cells. The permeablization step 
causes DNA/RNA leakage which causes cells to stick to the silicone tape seal. 
Bubbles and debris accumulation were also significant problems (Figure 3-12, Lane 
3). High negative pressures would result in cavitation and turbulence at channel 
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bifurcations (Lane 7). Large cell debris would often be trapped at the input port 
(Lane 8). If the velocity of the fluid was too low, the cells would settle at the bottom 
of the channel (Lane 4). Surface tension is high within fluidic channels as PMMA is 
hydrophobic. Although various surface modifications were attempted (Diaz-Quijada 
et al. 2007), the solution was determined to be a positive pressure flush with 1% 
Alconox. This is a detergent that lowers surface tension and flushes out cell debris. 
The use of a flow buffer and filtering the cells through a 40-µm mesh also helped 
dramatically in reducing clogs and cell sticking. EDTA and bovine serum albumin 
(BSA) binds to any non-specific ‘sticky’ epitopes and ions. OptiPrep (Iodixanol, a 
density gradient medium used for cell isolation) was used to density match the cells 
to prevent settling. This additive has a density of 1.320 ± 0.001 g/mL and is useful in 
suspending cells in buffer. The exact concentration was empirically determined. 
Higher concentrations result in slower velocities and clogged flow, lower 
concentrations result in cells settling to the bottom of the chip. 
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Figure 3-12. Common issues, bubble formation and cell debris. 
Various flow issues can be seen in the above images.  Images were taken at 40x 
magnification with widefield phase contrast microscope.  Cells can get stuck 
along the sidewalls, at the initial input port, also at bifurcations. Without 
proper filtering of the cells, large clumps of debris can also enter the channels 
and clog them up permanently. Each image is obtained from the input location 
of separate lanes as indicated by the labels (lanes 3 –  8).  
 
3.3.5 Data storage 
The PMC data sampling rate captures images at 14-bit depth at 60 kHz samples/s. 
Each sample is imaged for 2,500 scans at 12.5 scans/s (200s) resulting in a 22 MB 
data file for each color. However, much of these data are empty space, which we 
immediately discard (this includes the return scan of the galvanometer, the walls 
between the individual lanes, extra space at the outer edges of the lanes). To 
calculate the actual data that is stored on our hard drives, a single cell event from 
our method is a 160 pixel vector with a 14-bit depth which is equal to 280 Bytes. 
Each lane generates 300–400 raw cell images, which is about 110 KB per well. For a 
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two color assay, the total data is doubled to 220 KB. Including the data from feature 
calculations, an additional twofold requirement is needed for a total of 440 KB per 
sample. As such, our method is very efficient with regards to data requirements. The 
EMD Millipore ImageStream®X Mark II claims a data storage requirement of 500 
MB for 10,000 events (Millipore 2017). In comparison, 10,000 events in the PMC 
would only need approximately 13 MB. This is almost a 40-fold reduction in file size. 
 
 
  
52 
Chapter 4 - Aim 2 – Automated statistical workflow 
4.1 Introduction 
We designed a statistical workflow which is self-normalizing for high sensitivity 
with minimal cell count. We chose to automate the entire process to produce a 
single readout ‘activity score’ for each sample. By selecting the most relevant 
features from more than 150 image criteria, our algorithm condenses the 1-D image 
data into a single readout with a regression model. The ‘activity score’ is ideal for 
drug screening since assays often involve sifting through thousands or millions of 
compounds and measuring the drug response from each one. The ‘activity score’ is a 
necessity for screening applications to quickly understand the drug response from a 
single experimental condition. The statistical workflow is data efficient and 
eliminates subjective operator biases and/or complicated calibration. The 
algorithms are automatically calibrated to the specific controls being used. This 
allows for simple operation, rapid assay development, and on-the-fly data scoring. 
The true strength of our technology, when compared to existing HCS, shines in our 
speed, simplicity, and objectiveness of well scoring. 
4.1.1 Statistical nature of the PMC 
The PMC requires statistical algorithms to differentiate and profile cell populations. 
The way the PMC gathers 1-D data is highly variable by nature. The first source of 
variability is from flow. Because there is no hydrodynamic focusing in flow channels, 
cells will pass the laser at different heights and orientations. Each cell will be 
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scanned through a single random cross section as demonstrated in Figure 4-1. 
 
 
                                         
Figure 4-1. Possible scanning cross sections within a cell. 
Each cell is scanned by the laser through a random cross section. The colors 
red and green represent two separate fluorophores. On the left,  the cells are 
intersected by the excitation laser. The right hand side shows the 
corresponding 1-D image that is generated. Each color will be captured by a 
separate PMT. Image from (Mckenna et al.  2011). 
 
There is an inherent biological variability within each cell. This variability includes 
cell clumping, inconsistent staining, heterogeneity of cellular contents, and cell 
cycle. In addition to biological variance, there is optical noise from the laser, auto-
fluorescence of chip and background solution, electromagnetic interference, 
thermal/readout noise, and optical reflections/scattering.  
These factors add to the ‘noise’ of the 1-D approach which is why statistical 
analysis is ideal for this platform. Much of this noise can be systemically eliminated 
by selecting proper controls for each experiment. Normalization is critical in 
reducing persistent sources of variance. Analyzing distributions instead of 
Laser Path 
Fluorescent Cell 1-D Image 
  
54 
individual cells allows us to measure the characteristics of a cell population despite 
unknown variances. Changes in cellular phenotypes across a population will result 
in overall shifts in distribution mean or standard deviation. 
 
4.2 Statistical workflow 
4.2.1 Raw data and automatic thresholding 
As described in Chapter 3.3, raw 1-D images are collected and stored by the PMC 
after each run. For a cell to be classified as a successful event, it must have a peak 
intensity more than 6 standard deviations (SD) above the background. A single run 
produces about 300–400 events per sample. It has to satisfy a certain range for 
nuclear width and must contain only one peak. This range is indicative of proper 
focusing and correct size for a T cell. Any events that are double scanned by the 
laser are also removed. Each cell is fitted to a Gaussian curve and the R2 value must 
be higher than 0.95. The thresholding procedure is summarized in Figure 4-2. 
 
Figure 4-2. Threshold for a qualified event. 
Cells must pass certain parameters before being considered as a qualified event 
for analysis. µ and are the mean and standard deviation of the background 
intensity. R2  is the coefficient of determination of a Gaussian curve fit to each 
1-D cell image. This is to ensure that each cell is properly focused, a singlet, 
and is the correct shape and size for a T cell.  
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As mentioned above, each sample is loaded with about 8,000 cells but only 300–400 
events are captured from each sample. This is a hit rate of about 5% of the total cells 
that flow through each fluidic channel. However, we have shown previously that this 
is more than enough events to reliably characterize a sample (McKenna et al. 2011). 
The distribution generated from each well is reproducible and mostly normal 
(additional analysis in further sections). An example of a typical raw output from the 
PMC is in Figure 4-3. 
            
Figure 4-3. Raw data output from a single run.  
8 lanes are being scanned for 2,500 scans. Each row of data represents a new 
scan imaged by the PMC, which is a function of time. The x -axis represents the 
specific laser location across a 4mm detection zone, which i s also a function of 
time. Each white line indicates a cell that has passed the automatic threshold 
requirements and will be stored in a database. 
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4.2.2 Feature generation 
For each qualified event, “features” are generated and pre-filtered before further 
analysis. The background noise floor is subtracted first. Compared to background 
subtraction from 2-D HCA, 1-D background subtraction is trivial and does not 
require any complicated edge detection or contrast gradients or averaging. 
Subtracting the background noise is as simply as subtracting the next row. Each row 
of pixels directly underneath an event will contain the same electronic, spatial, and 
fluorescent noise. Each image is also smoothed with a 3 pixel window using the 
SGO-LAY algorithm in Matlab. Before any feature is calculated, each event is 
normalized to a unitless height of 1 by dividing by its own peak intensity. Any data 
below 20% of the peak is discarded. This is because the laser spot size is 2 µm in 
diameter. Each 1-D image can be thought of as a convolution of the laser spot and 
the internal fluorescence. As the laser is approaching a cell, there is residual 
fluorescence that is excited due to the relative size and proximity of the laser spot. 
As confirmation of this optical effect, each 1-D image is roughly 2–4 µm wider than 
the actual size of the T cells.  
Next, hundreds of morphological features are generated from each 1-D cell 
event. These features have been adapted from commonly used features in 2-D HCA 
(Ng et al. 2010; Carpenter et al. 2006). A visual representation of how our features 
are calculated is shown in Figure 4-4. 
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Figure 4-4. Feature calculation for a typical 1-D event. 
Features are calculated from each 1-D image that are representative of the 
underlying localization of biomarkers.  The 2-D analogue is shown above the 1-
D image. Features such as perimeter, area and full width half max (FWHM) are 
calculated and similar to their 2-D analogues. Image from (Wang & Ehrlich 
2017) 
 
These features include but are not limited to: area, perimeter, full width half max 
(FWHM), upper and lower 25th/75th widths, left/right top/bottom symmetry, 
smoothness, roundness, slope, inflection point, cytoplasm vs. nuclear regions, and 
Gaussian fit statistics. Each feature is repeated for each PMT channel as well as 
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inter-comparisons between PMT channels. These features attempt to provide a full 
comprehensive characterization of each 1-D curve. In this way, one can preserve the 
informational content of biomarker localization within each cell. A full list and 
summary of the features is provided in Appendix 7. 
 All the features are compiled into histograms and then normalized to a 
control well. The negative control is run twice, once to generate a control well 
baseline distribution, and again to generate the actual negative control distribution 
for the experiment. Normalizing to a control well reduces spatial variance from chip 
defects or laser/well position. Features are converted into a Z-score by subtracting 
the mean from the control sample and then dividing by the SD (Figure 4-5). Extreme 
outliers greater than 4 SD are removed from each distribution. An example of the 
final normalized distribution for a single feature is in Figure 4-6.  
 
Figure 4-5. Normalization to control well to reduce spatial variance. 
µ and  are the mean and standard deviation of the control well.  Z represents 
the mean Z-score for each event j.  Feature distributions are compiled and a 
mean statistic is calculated for each feature i .  n is the total number of events 
per sample. 
 
The mean statistic calculated for each feature distribution to form a set of 
normalized features for each sample. Initially, the underlying distributions were 
unknown in the PMC so non-parametric statistics were used to analyze feature 
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distribution. The Kolmogorov-Smirnov (KS) statistic is a measure of the maximum 
distance between two cumulative distribution functions (CDF) (Green line depicted 
on Figure 4-6) (Dragiev et al. 2011). After a certain point, the PMC protocols were 
optimized to generate normal distributions so the mean statistic was used in place 
of the KS statistic for the majority of our assays. 
 
Figure 4-6. Feature distribution for a single feature. 
Black represents cells from a negative control. Red represents cells from a 
positive control. The changes in shape and mean indicate an underlying shift in 
the phenotype. Left) Typical normal histogram generated from a single well for  
a single feature. Right) The same distribution but represented as a cumulative 
distribution function (CDF) and KS statistic (green). Each line in the CDF is a 
separate replicate. All features are normalized to a Z -score (SD) so that 
features can be compared with each other.  
 
4.2.3 Post filtering 
After the mean statistic is calculated for each feature, the set of features is filtered to 
eliminate those that fail two separate statistical significance tests. Since we only use 
the mean statistic from each feature distribution, we have to confirm our 
assumption of a normal distribution.  The first test is a normality test (one-sided 
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Kolmogorov–Smirnov test) to remove all non-normal features at α = 0.05. The 
second test applies a paired student t-test between each negative control feature 
and its corresponding control well at α = 0.05. A control well is just the negative 
control run a second time. Any feature that fails the null hypothesis is removed from 
consideration since any significant difference would imply an operational failure.  
4.2.4 Feature selection 
After invalid features are removed, the next step is to select a subset of the 
remaining features for regression modeling. Each feature can be thought of as a 
separate dimension or degree of freedom. Dimensionality reduction is one of the 
core principles of HCA since enormous amounts of data can be generated from every 
image. To reduce the complexity and size of the data set, we begin by eliminating 
features that are least ‘important’. Each feature is ranked according to the difference 
between the mean statistic of the positive and negative samples. Feature selection is 
implemented based on minimal redundancy maximum relevance model (mRMR). 
Many other feature selection algorithms (such as principle component analysis, 
factor analysis, support vector machine, linear discriminant analysis) were 
considered but the mRMR model was the least computationally expensive. The 
mRMR has been used successfully in other HCS assays and shown to maintain high 
statistical power (Peng et al. 2005). A flow chart showing the feature elimination 
process is shown in Figure 4-7. The mRMR algorithm iteratively selects the highest- 
ranking feature, and removes all other correlated features with a Pearson’s 
  
61 
correlation coefficient r > 0.5. This is repeated until all features are exhausted or the 
number of features exceeds the logistic regression over-fitting limits. 
 
 
Figure 4-7. mRMR model for feature selection. 
A) Flow diagram showing the feature elimination process  of the mRMR model. 
Features are ranked from highest ranking feature to lowest ran king feature.  
The top feature is selected and removed (yellow).  Features that are correlated 
to previous chosen features are removed to reduce collinearity  (grey). The loop 
is continued until there are no more features. B) Graph that shows the 
remaining selected features (yellow) from part A. Images from (Wang & Ehrlich 
2017). 
 
A 
B 
  
62 
4.2.5 Logistic regression model 
In the final step, the most relevant features that remain are used to generate a 
binomial logistic regression weighted “classifier”. Logistic regression estimates the 
probability that a set of features belongs to a single binary dependent variable (a 
positive or negative control sample) based on the weights of multiple independent 
predictors (these would be the relevant features). We use this probability to 
represent the ‘activity score’/drug response from a sample. The activity score is the 
linear combination of the features multiplied by their corresponding weighted 
coefficients (Figure 4-8). 
                     
Figure 4-8. Activity score readout defined in terms of logistic regression. 
The equation on the right is the probability function of  logistic regression. 
Coefficients are found by using the maximum likelihood estimation which 
entails finding the set of parameters for which the probability of the observed 
data is the greatest.  
 
Logistic regression is well suited to simulate an “activity score”. In our assays, we 
always have a positive and negative control sample, and are attempting to 
understand the drug response with respect to these two populations in a 
probabilistic framework. The logistic regression also generates a continuous output 
variable so it can help differentiate between intermediate phenotypes. This is useful 
for temporal or dose response studies. 
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A complex phenotypic response from a population of cells can be defined by 
a simple quantitative readout using our modified logistic regression model.  This is 
useful for screening due to the single continuous output. It is also completely hands-
off. The only supervised operation is labeling each sample as a positive, negative, or 
drug response. The algorithm runs through the entire statistical workflow without 
any intervention. Since it is does not require previous knowledge of any phenotypes 
from the control samples, the model is essentially ‘sample-blind’. This allows the 
model to adapt to any new assay effortlessly, as long as the proper positive and 
negative control samples are selected. A ‘sample-blind’ approach does not need 
manual analysis which allows for rapid assay development.  
We performed a detailed analysis for algorithmic performance of our initial 
classifier in a previous paper (Cheung et al. 2015). Using separate training and test 
sets to construct confusion matrices and calculating common metrics such as 
accuracy and specificity, we determined that all metrics were near 100% or 0%. A Z’ 
> 0.5 indicates a 12 SD separation which is essentially error free. A Z’ = 0.0 indicates 
a 6 SD separation which is equivalent to a false positive rate of 0.15%. To minimize 
overfitting, we collected at least 5 events per explanatory variable (EPV). For logistic 
regression, it is typically assumed that a minimum of 10 EPV is required for a stable 
model. However, there are sources that have used 5–9 EPV with minimum Type I 
error rates (Vittinghoff & Mcculloch 2007). Our 5 EPV was chosen mainly due to 
practical reasons. Since our model generally picks 4–6 features, this would require 
40–60 replicates for each control. 
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4.3 Quality control metrics 
The separation strength between positive and negative controls is evaluated using 
Z’ and strictly standardized mean difference (SSMD) as shown in Figure 4-9 (Zhang 
et al. 1999; Zhang 2007). 
                                                  
Figure 4-9. Equations for Z’ and SSMD. 
Z’ and SSMD are commonly accepted quality control metrics for large screening 
assays. µ and σ are the mean and standard deviation for either positive (p) or 
negative (n) control.  
 
A Z’ > 0.5 is generally used in assays with very strong positive and negative controls 
such as ELISAs, binding assays, and other similar chemical assays (Bray & Carpenter 
2004). However, for imaging assays where the results are much more complex and 
closer in phenotype separation, SSMD is preferred (Bray & Carpenter 2004). In this 
case, for medium to strong controls, a SSMD > 6 is considered sufficient. For weak 
controls with minimal separation, SSMD > 3 is considered sufficient. With respect to 
T cell activation, high separation values imply a large shift in biomarker spatial 
localization. This can be construed as a ‘healthier’ cell population with a strong T 
cell activation response. Low separation values would imply a more ‘anergic’ non-
responsive cell population, with respect to T cell activation. 
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Chapter 5 - Aim 3 – Assays 
5.1 Introduction 
The first sections have focused mainly on the instrumentation and data analysis for 
the PMC.  This section progresses to the assays we developed by utilizing the PMC 
platform. One target application of this work is to construct an anergy assay in 
primary T cells to study the immune checkpoint pathway, so a series of preliminary 
validation assays were designed with that goal in mind. In order to study and screen 
for immunotherapy drugs, we needed to design an assay to systematically probe 
drug responses from immuno-compromised cells. One of the main difficulties in 
probing immuno-compromised cells, is that compromised cells naturally have a 
negative phenotype and lack of drug response. Therefore, we needed a method to 
induce immuno-compromised cells alongside healthy responsive cells, and to 
compare the relative drug response from both phenotypes. 
5.1.1 Motivation  
The goal of immunotherapy is to restore immuno-compromised/anergic T cells 
(Marincola et al. 2003). Any assay that attempts to study anergic T cells must be able 
to differentiate between strong and weak immune responses. Traditional methods 
of measuring immune response include surface marker analysis (ki67/CD25/CD69), 
cytokine analysis (IFN/IL-2), CFSE, and cell cycle count (Suni et al. 2005). While 
these are effective at measuring proliferation status, they do not directly measure 
the functional/dynamic state of an immune cell. Measuring the functional immune 
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response of a T cell can provide useful information about internal signaling or 
transcriptional events. In this work, the translocation of certain transcription factors 
will be used to measure a functional immune response. There are many studies that 
show correlation between strong TCR activation and proliferation status (Smith-
Garvin 2009). On the other hand, immuno-compromised T cells can contain many 
defects in TCR signaling markers and activation (Schwartz 2003; Blackman et al. 
1991; Poltorak et al. 2013). Cells can encode various analog parameters to modulate 
their own activation, which can include factors such as intensity of nuclear 
translocation, response time, duration, and number of oscillations (Covert 2011). 
Nuclear import is regulated by the phosphorylation of various proteins (Nardozzi et 
al. 2010). 
All the above are reasons why functional information about a cell state is 
more informative than static measurements of overall gene/receptor expression. 
Knowledge of the internal signaling pathways of a cell can provide crucial 
information in understanding new drug interactions. In the pursuit of developing a 
better type of screening assay, our approach focused on measuring dynamic 
localization of transcription factors during drug responses. A high content screening 
assay based on biomarker localization should result in more accurate drug 
discovery, better understanding of underlying mechanisms, and fewer false 
positives and wasted effort on ineffective drugs. 
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5.1.2 Overview 
We present the following assays in order of biological importance with respect to 
the immune checkpoint pathway. Initial assays focused on the events immediately 
preceding and following TCR ligation/activation (0–40 min after activation). This is 
important as a test of feasibility in differentiating between subtle phenotypes using 
the PMC. More importantly, the translocation of transcription factors NF-kB and 
NFAT occur during this 0–40 min time frame. After confirming successful detection 
in a Jurkat cell line, assays were repeated using primary T cells. Many difficulties 
had to be addressed due to the issues mentioned previously in Chapter 2.3. After 
validating our methods in primary cells and adjusting them accordingly, we created 
a protocol to systematically test multiple drug responses of immuno-compromised 
cells. We started by artificially inducing PD-1 expression in primary T cells. Then, we 
created separate positive and negative control populations in order to compare 
relative drug responses from multiple drug candidates. The primary drug we 
wanted to investigate was anti-PD-1, an immune checkpoint blockade drug that has 
shown potential in recent clinical trials. Immune checkpoint blockade treatment 
should partially or fully restore cells from an immuno-compromised state. A 
successful drug response would be expected to resemble cells from a healthy 
population (negative control), instead of an anergic population (positive control).  
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5.2 T cell activation/capping 
In general, T cell activation events occur during every immune response so we 
decided early on that this should be the first pathway to investigate. In addition, we 
hypothesized that the functional state of the activation pathway should indicate 
proliferation status (healthy vs. anergic). 
  Although our final goal was to probe drug responses from primary human 
cells, it is standard to first validate an assay in a relevant cell line or animal model. 
Jurkats are naturally suited for this task. Much of what we know about T cell 
activation signaling is the work of Arthur Weiss on Jurkat cell lines. Also, detecting 
the capping phenotype would validate the ability of the PMC to measure spatial 
localization. In a standard non-imaging flow cytometer, capping is undetectable as 
the overall number of TCRs do not change, only the spatial phenotype changes. 
5.2.1 Methods 
Cells were labeled with primary antibodies against CD3 (eBioscience #14-0037, 
OKT3 clone, 5 µg/mL) and CD28 (eBioscience #16-0289, CD28.2 clone, 2.5 µg/mL), 
on ice; secondary antibodies are added to crosslink primary antibodies (Invitrogen 
anti-mouse IgG #A16074, 20 µg/mL). Capping was induced by submerging samples 
in 37˚C water bath for 0 to 20 min. The negative control (0 min) remained on ice and 
was fixed immediately without any induction. Cells were removed from the water 
bath at 2 min, 5 min, and 20 min time points. The reaction was stopped and fixed by 
addition of 1 mL of ice-cold PBS with 100 µl of 37% formaldehyde (10 min at 25˚C). 
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Secondary antibodies were conjugated with a single dye, Alexa 488, so only one 
PMT channel (features are represented with PMT2 suffix) was used. Cells are 
imaged as described in Chapter 3. Features are calculated as described in Chapter 4 
and are compiled into histograms below. KS-statistics are generated between 
positive and negative controls and visualized as a heatmap for easier analysis. For 
validation, cells are imaged using standard 2-D widefield microscopy. 
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5.2.2 Results 
 
Figure 5-1. Histograms for selected features from Jurkat capping experiments. 
Red is negative control (0 min induction), Blue is the positive control (20 min 
after induction). Nine features are chosen as a representative set to 
demonstrate the overall shift in features. X-axis for each feature is unique for 
each feature as none of the features are normalized. Y -axis is the total cell 
counts for the histogram. PMT 2 is the green PMT channel that indicates CD3 
spatial location (Alexa 488). The shift in distributions are indicative of 
underlying spatial  changes in phenotype.  
 
  
71 
 
 
Figure 5-2. Temporal plot for selected features during capping.  
Each plot shows the shift in feature means over time, 0–20 min. All features are 
the same as in Figure 5-1 to show the relative temporal shifts. A linear 
regression line is fitted to each set of feature means. The trend line shows the 
general trend of how the features are evolving over time  and are consistent 
with the trends in Figure 5-1. Vertical bars represent the SD from each feature 
histogram (200–300 cells). 
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Figure 5-3. PMC data for TCR capping response in Jurkats. 
A) KS values from representative features indicate the strength of separation 
between the positive and negative controls, in this case, ( -/-) is the distance 
between negative and negative. As e xpected, there should be little to no 
separation between negative controls . For the (-/+), the negative control at 0 
min is compared to the capping phenotype at 20 min. Higher KS for peak, 
FWHM, roughness, area, and roundness indicate higher separation. B)  
Representative 2-D fluorescent images taken at 1000ms exposure, 40x 
magnification, 488nm/530nm ex/em filters. Top image shows diffuse 
distribution of T cell receptors. Bottom image shows aggregated TCR 
complexes, the phenotype associated with capping.  
 
 
The 2-D microscopy images from Figure 5-3B show surface redistribution of TCR 
complex at both cell rest and 20 min after induction. Histograms from selected 
features are shown in Figure 5-1. Shifts in the feature distributions indirectly 
A B 
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represent changes in the underlying capping phenotype. Both peak intensity and full 
width at half maximum (FWHM) decreased slightly. The reduction in overall 
intensity was unexpected. Since the aggregated of TCR complexes contain the same 
number of receptors but in a smaller area, it was expected that the average intensity 
should have increased. This discrepancy may be due to the size of the laser spot. The 
laser is a 2 µm wide beam that scans only a small portion of the whole T cell. If the 
fluorescence is localized to smaller areas on the surface, it can be missed or only 
partially scanned in the case of diffuse receptor distribution. Another possibility 
could be endocytosis of TCR receptors. After the initial immune synapse, the TCR is 
downregulated and sequestered within the cytoplasm, this may lead to a reduction 
in overall fluorescence.  
On the other hand, width and area features behaved as expected. Capping of 
the TCR should result in smaller pockets of fluorescence, and therefore should lead 
to statistically ‘thinner’ 1-D images. For both slope and perimeter, there were subtle 
changes in the overall shape of the distributions but the connection to actual biology 
is difficult to explain. Also noticeable was that most of the symmetry based features 
showed little to no changes in distribution. This is reasonable due to the 
randomness of the cell orientation during imaging. Any features related to the 
internal symmetry within a cell would be lost when summed across an entire 
population. In Figure 5-2, the means from each feature were plotted as a function of 
time. These plots confirm the same trends within the data as compared to Figure 
5.1. 
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 Because of the lack of normality in the feature distributions, the KS statistic 
was used to quantify the separation between negative and positive samples. The KS 
statistic was calculated from both negative vs. negative and negative vs. positive. 
The results are plotted as a heatmap for better visualization in Figure 5-3A. In the 
negative vs. negative column (-/-), features showed no significant differences 
between samples (p-value data not shown). However, for the negative vs. positive 
capping response (-/+), many of the features showed highly significant differences 
(p-values are not shown). Even though early algorithms did not use normalized 
features, the results from the capping experiments was a strong indication that the 
PMC could detect changes in spatial localization with high statistical significance. 
 
5.3 NF-kB Translocation 
Next we chose to measure NF-kB translocation in Jurkat cells. NF-kB is a critical 
transcription factor that translocates to the nucleus shortly after T cell 
activation/capping. It is involved in many signaling pathways that are crucial to T 
cell regulation and proliferation (Gerondakis & Siebenlist 2010). TCR activation, 
Toll-like receptors, cytokine receptors can all trigger NF-kB translocation. 
Measuring the spatial phenotype of a transcription factor is more informative of 
immune state than measuring surface receptor distribution. Since our primarily goal 
is to test the functional response of T cells, it makes sense to directly track the 
movement of important signaling molecules after initial T cell activation. Compared 
to TCR capping, translocation of NF-kB should be harder to detect as the nuclear 
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compartment is relatively large in T cells. This should help validate the ability of the 
PMC to detect more subtle changes in spatial localization within small suspension 
cells. 
5.3.1 Methods 
The protocol to induce NF-kB translocation is very similar to capping. The main 
difference is the duration of the stimulus and the proteins being labeled. Cells were 
resuspended in 1.5-mL tubes in 100 µL of C10 media for 30 min on ice. C10 media is 
RPMI 1640 (Invitrogen #12633-012) supplemented with HEPES, Glutamax, 
antibiotic/antimycotic, and 10% fetal bovine serum (FBS). For the positive control, a 
two-step TCR crosslinking was used, 5 µg/mL mouse anti-CD3 OKT3 (eBioscience 
#16-0037) and 2.5 µg/mL mouse anti-CD28 (eBioscience #16-0289) were added 
and incubated with the chilled cells for 30 min on ice. Negative controls used 
unlabeled mouse IgG isotype control in place of primary antibodies. Goat anti-
mouse IgG (20 µg/mL, Invitrogen #A16074) was added to both controls and 
allowed to crosslink for another 30 min on ice. Both conditions were incubated in a 
37˚C water bath for 0–30 min. To stop the translocation response, cells are removed 
and fixed by adding 10ul of ice-cold 37% formaldehyde. Cells are stained with a 
polyclonal anti-NFkB p65 (Abcam #ab16502, 1 µg/mL) overnight. Secondary 
staining was completed with a single color, anti-rabbit IgG Alexa 488 (Invitrogen 
#A11008) and imaged as described in Chapter 3. Similar to capping, features are 
generated and presented as histograms. KS-statistics are generated between 
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positive and negative controls and cells are imaged using standard 2-D widefield 
microscopy. 
5.3.2 Results 
 
                                               
Figure 5-4. Histograms for selected features from NF-kB translocation. 
Blue is the negative control which represents resting NF -kB. At rest, NF-kB is 
contained in the cytoplasm as it is inhibited by IkB. Red is the positive control 
which represents NF-kB localization after 30 min of induction with CD3/CD28 
antibodies. Nine features are chosen as a representative set to demonstrate the 
overall shift in features. X-axis for each feature is unique for each feature as 
none of the features are normalized. Y-axis is the total cell counts for the 
histogram. All features are calculated from the green PMT channel that 
indicates NF-kB spatial localization (Alexa 488).  
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Figure 5-5. PMC data for NF-kB translocation in Jurkats.  
Left) KS statistic heatmap for most relevant features. Right) 2-D widefield 
images using standard fluorescent microscopy (60x, GFP ex/em filter). The 
upper image is NF-kB at rest. The lower image is NF-kB localization after 30 
min. Similar to the data from capping, KS values are visualized as a heatmap. 
For the (-/+), the negative control at 0 min is compared to the  state of NF-kB 
translocation after 30 min. Surprisingly, the  KS values are much higher for all 
the features when compared to the capping phenotype.  
 
It was initially expected that the width and area features for NF-kB translocation 
should be lower after 30 min of induction, since in theory, the NF-kB should 
completely relocate to the nucleus. However, the data showed exactly the opposite. 
The width (FWHM) of the translocation response actually increased, while overall 
peak intensity decreased (Figure 5-4). Other features such as area, roundness, and 
perimeter all showed significant increases in overall values. This change in 
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phenotype was confirmed with 2-D microscopy (Figure 5-5). It was observed that 
translocation of NF-kB led to a more uniform concentration of NF-kB across the 
cytoplasmic and nuclear compartments. After searching the literature, it was found 
that the cytoplasm to nuclear ratio (C/N) does not go from 1 to 0, but more like 1 to 
0.5 (Beg et al. 1993; King et al. 2011). While it is possible that the uniform 
phenotype we saw could be a result of staining errors, the more likely explanation is 
that soluble CD3/CD28 induction of NF-kB in vitro is weaker than true physiological 
induction. This makes sense as the protocol does not use antigen-specific TCR 
ligation, but instead binding to the CD3 peptide chain that is connected to the TCR. 
 Another interesting observation is that the NF-kB translocation resulted in 
higher separation between positive and negative phenotypes. This is demonstrated 
by the larger KS values obtained from the feature distributions (Figure 5-5). One 
possible reason is that there are many more molecules of NF-kB than TCR receptors. 
This indicates a higher volume of NF-kB fluorescence compared to TCR 
fluorescence. In addition, NF-kB is a molecule that is evenly distributed throughout 
the entire cytoplasmic volume. Volumetric spatial changes should be relatively more 
pronounced than surface redistribution changes. No matter the underlying cause, 
these experiments reinforced the choice to use translocation of transcription factors 
for our functional readout of T cell dynamics. 
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5.4 Transition into primary cells 
Once we confirmed that NF-kB translocation could be strongly detected with the 
PMC, the next step was to repeat all the experiments in primary cells. TCR capping is 
not as physiologically relevant for drug response assays, compared to NF-kB 
translocation, so it was decided that future assays would strictly use NF-kB as the 
readout. As mentioned in Chapter 2, the use of PBMCs and primary human T cells 
has additional challenges. Cells purified from peripheral blood are more 
heterogeneous than cell lines and can have unknown genetic variations from donor 
to donor. Therefore, it was important to purify as many T cells as possible from a 
single donor. We decided to isolate both CD4+ and CD8+ T cells from each donor. 
This allowed for the maximum number of T cells purified from a single donor with 
minimal effect on heterogeneity. As for the NF-kB induction, T cell activation using 
CD3/CD28 should be identical in primary T cells. 
 
5.4.1 Methods 
 
Before inducing NF-kB translocation, the first step was to obtain purified primary 
human T cells. Buffy coat collars were obtained from adult human blood donors 
from Boston’s Children’s hospital. RosetteSep CD3+ negative selection enrichment 
cocktail (Stemcell #15021) was added at a ratio of 50 µL of antibody cocktail to each 
mL of whole blood then incubated for 30 min at 25˚C. Samples were diluted with 
equal parts PBS + 2% FBS (Invitrogen #10082-139), then combined with DM-L 
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density gradient (Stemcell #15705) into 50 mL SepMate tubes. Tubes were 
centrifuged at 1200g, and supernatant was collected. Cells were combined with 
aluminum chloride for 10 min at 25˚C to lyse red blood cells. Freshly purified cells 
were frozen immediately in standard freezing media (10% DMSO, 90% FBS) at 2 x 
107 cells/mL density and maintained in liquid nitrogen. 
Cells were characterized to consist of roughly 95% CD3+ cells: 50% of those 
were CD4+ and the other 50% were CD8+. Cell viability was confirmed to be >95% 
with trypan blue and a manual hemocytometer (data not shown). On average, 50–
150 million purified CD3+ T cells were obtained from each individual donor. Each 
experimental condition needed about 1 million cells, taking into account cell loss 
due to staining and washing steps. After performing the assay, each sample could be 
imaged up to 125 replicates with our reduced PMC volume requirements. 
The protocol for NF-kB translocation in primary T cells was nearly identical 
to that of Jurkats. Cells were resuspended in 1.5-mL tubes in 100 µL of C10 media 
for 30 min on ice. For the positive controls, a two-step TCR crosslinking was used, 5 
µg/mL mouse anti-CD3 OKT3 (eBioscience #16-0037) and 2.5 µg/mL mouse anti-
CD28 (eBioscience #16-0289) were added and incubated with the chilled cells for 
30 min on ice. We used additional compounds to induce NF-kB translocation. These 
were substituted in place of the standard CD3/CD28 antibodies: 200 ng/mL of 
TNFa, 10 µg/mL of Phorbol 12-myristate 13-acetate (PMA) + 10 mM of Ionomycin, 
10 µg/mL of Phytohaemagglutinin (PHA), 10 µg/mL Lipopolysaccharide (LPS), and 
1 µg/mL Staph Endotoxin B were all tested as NF-kB induction compounds. 
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Negative controls used unlabeled mouse IgG isotype control in place of primary 
antibodies. Goat anti-mouse IgG (20 µg/mL, Invitrogen #A16074) was added to all 
samples and allowed to crosslink for another 30 min on ice. All conditions were 
incubated in a 37˚C water bath for 0–30 min. To stop the translocation response, 
cells are removed and fixed by adding 10ul of ice-cold 37% formaldehyde. Cells are 
stained with a polyclonal anti-NFkB p65 (Abcam #ab16502, 1 µg/mL) overnight. 
Secondary staining was completed with two colors, anti-rabbit IgG Alexa 488 
(Invitrogen #A11008) for the green PMT channel and PI for the red channel. PI and 
RNase A were added to the mix and incubated for 30 min at 37˚C to serve as a 
nuclear counterstain to NF-kB. Cells are imaged using widefield fluorescent 
microscopy. Feature distributions for the highest-ranking features are displayed as 
cumulative distribution functions.  
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5.4.2 Results 
 
 
Figure 5-6. 2-D microscope images of various NF-kB induction methods.  
The induction stimulus is labeled underneath each image. Control represents 
NF-kB translocation using standard CD3/C28 antibodies. Green color is anti -
NF-kB conjugated to Alexa 488. Red is propidium io dide (PI) for the nuclear 
stain. The images here shown mainly failed NF-kB translocation in all induction 
methods. For a successful NF-kB translocation phenotype, the green channel 
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(NF-kB) should overlap with the red channel (PI) which indicates that the NF -
kB p65 homodimer has diffused into the nuclear compartment. In each image, 
the opposite occurs. The NF-kB remains contained in the cytoplasmic 
compartment, this can be seen by a large empty circle  in the green channel.  
 
 
Figure 5-7. Cumulative distribution function and histogram for the highest separated 
features from NF-kB translocation in primary T cells. 
CDFs for the control induction of NF-kB in primary T cells. The two features 
listed above (Left Cyto Area and Left Perimeter) had the highest difference in 
mean statistics, but showed no significant changes between negative and 
positive samples. Each red line is a separate replicate sample from the positive 
NF-kB induction (30 min). Each black line is a separate replicate sample from 
the negative NF-kB induction (0 min).  A quick glance at the shifts in feature 
distributions between negative and positive samples shows that NF-kB 
translocation in primary T cells was minimal. CDFs are represented as 
histograms on the right for an alternative visual.  
 
Unfortunately, NF-kB translocation did not respond similarly in primary cells when 
compared to Jurkat cells. Even after testing with multiple induction compounds, 
none of the primary cells showed any clear translocation response. We performed 
multiple experiments in an attempt to strengthen the NF-kB translocation response. 
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For example, we tried expanding the T cells first, and then inducing NF-kB 
translocation but the results were the same. Microscopy confirmed a lack of 
observable changes in spatial localization of NF-kB (Figure 5-6). This was also 
confirmed in the data analysis, the positive and negative feature histograms 
overlapped completely with almost no separation (Figure 5-7). The CDFs also 
showed little to no change in the mean statistic. The corresponding KS and p-values 
were also near zero (data not shown). 
The lack of a translocation response was unexpected as other research 
groups have successfully induced NF-kB translocation in primary T cells and 
confirmed their results with western blots (Lupino et al. 2012). However, looking 
closer at the literature, most protocols involve stripping the cytoplasm from the cell, 
and only measuring nuclear concentration of NF-kB (Beg et al. 1993). It is much 
more sensitive to measure pure NF-kB accumulation in the nucleus since it starts at 
zero. Other protocols compare phosphorylated IkB/NF-kB. Since western blots 
separate proteins based on molecular weight and charge, the difference between 
IkB-NF-kB and NF-kB is much more pronounced. After talking to colleagues in the 
Biology department, there was further support that NF-kB translocation is in fact 
much weaker in primary cells (Gilmore & Gerondakis 2011). The C/N ratio goes 
from 1 to 0.9, as opposed to Jurkats, where the C/N goes from 1 to 0.5. Because the 
spatial phenotype is so weak in primary cells, most people avoid using microscopy 
to measure NF-kB translocation. Since NF-kB translocation spatial phenotype was 
too subtle to be detected in the PMC, an alternate method had to be found.  
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5.5 NFAT translocation 
Because the NF-kB translocation response was undetectable in primary T cells, we 
had to find a new biomarker for the PMC assay readout. Nuclear Factor of Activated 
T cells (NFAT) was chosen for its relevancy in T cell activation (Smith-Garvin 2009). 
NFAT is also a translocating transcription factor (along with AP-1 and STAT1) that 
occurs directly after TCR ligation. One crucial difference from NF-kB is that NFAT 
translocation occurs much faster (Poltorak et al. 2013). NFAT is also not as 
ubiquitous in other signaling pathways. 
 
5.5.1 Methods 
The protocol for NFAT translocation was similar to NF-kB translocation but had 
some key differences. Two methods were used: the first approach used standard 
CD3/CD28 antibodies to bind to the TCR as described in 5.3.1, the second approach 
used PMA/Ionomycin to trigger NFAT translocation. NFAT translocation involves 
the activation of calcineurin and calcium signaling. Therefore, PMA/Ionomycin can 
be used to artificially induce NFAT translocation while bypassing the TCR activation 
pathway. This served as a useful control against the standard CD3/CD28 activation 
in case unexpected phenotypes occurred.  
Cells were incubated on ice as before, but 10 mM of ionomycin (Sigma # 
I0634) and 1 µg/mL phorbol myristrate acetate (PMA) (Sigma #P8139) were used 
instead of CD3/CD28 antibodies. The positive sample was similarly placed in a 37˚C 
water bath for 20 min to induce translocation of NFAT and fixed with the same 
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protocols. For the primary antibody, rabbit anti-NFAT1 (CST #4389, 2 µg/mL) was 
added and incubated overnight at 4˚C. Then, secondary anti-rabbit Alexa 488 
(Invitrogen #A11008, 10 µg/mL), 1:100 PI, and 20 µg/mL of RNase A were added to 
the mix and incubated for 30 min at 37˚C. The PI and RNase provide a nuclear 
counterstain against the single green channel of anti-NFAT Alexa 488. Using a 
counterstain allows features to be normalized against themselves and is more 
resistant to differences in staining and biological variance. We specialized to two-
color assays from this point on, as we discovered that PMT-to-PMT comparisons are 
intensity independent and easier to normalize. 
During these experiments, we pushed our instrument to higher sample 
throughput. Lack of sample throughput is a significant limitation that is preventing 
adoption of 2-D imaging cytometry and primary cell assays in drug screening 
(Zanella et al. 2010; Eglen & Reisine 2011). With screening libraries up to millions of 
compounds, a single large scale screen can cost hundreds of millions of dollars for 
reagents. This is why throughput, volume requirements, data storage are all 
important when developing a screening assay. Volume and data requirements have 
already been addressed in previous chapters. One of the goals of the PMC is to help 
develop screening assays, so the PMC must be adapted to high throughput 
operation. 
Each induction method (PMA/Ionomycin and CD3/CD28) was applied to a 
large population of naïve primary T cells. Each approach was imaged in the PMC to 
simulate a 96-well plate: 48 negative controls and 48 positive controls were 
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obtained for each induction method. This is similar to a standard 50/50 plate assay 
quality control metric. For this particular data set, only the central 8 lanes were 
used for all samples. Each chip turnover took about 3 min to finish, 2 min for 
scanning and 1 min for cleaning.  
After collecting all the data from all samples, a separate population of only 
negative (0 min) and positive (20 min) controls were used to generate the 
coefficients for the activity score regression model. Instead of generating KS-
statistics, activity scores were calculated using those coefficients from the 
regression model. The activity score represents the relative strength of NFAT 
translocation compared to the positive and negative controls, and is much more 
suitable for high-throughput analysis. The selected coefficients (Figure 5-9) were 
applied to all the samples equally for both induction methods to generate a single 
activity score for each sample. Z’ and SSMD values were used to measure the quality 
of the induction method and results are presented below. Cells are imaged using 
widefield fluorescent microscopy for validation. 
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5.5.2 Results 
 
     
Figure 5-8. 2-D images of NFAT translocation in primary T cells using PMA/Ionomycin 
induction.  
Green is Alexa 488 staining for NFAT1. Red is PI, nuclear counterstain. A) 
Negative control  – Cells at rest (0 min) that have mostly cytoplasmic NFAT. 
There is a strong distinction between cytoplasmic and nu clear fluorescence.  B) 
Positive control –  Cells that have been induced for 20 min. NFAT has diffused 
into the nuclear compartment so there is more overlap between green and red 
PMT channels.  
 
A B 
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Figure 5-9. CDFs for selected features that are highly separating between negative and 
positive NFAT translocation in primary T cells. 
CDFs and corresponding histograms for the top 6 features as selected by the 
regression model. Each red line (N=8) is a separate replicate sample from the 
positive NFAT induction (30 min). Each black line (N=8) is a separate replicate 
sample from the negative NFAT induction (0 min). The features and their 
corresponding coefficients were used to create an activity score model and 
applied to all samples. Visual inspection shows significant shifts in the mean 
statistic. P1/P4 represents the ratio of the features between the red nuclear 
channel (PMT1) and the green NFAT channel (PMT4).  
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Figure 5-10. Activity score box plots for both PMA/Ionomycin and CD3/CD28 activation of 
NFAT translocation in primary T cells. 
Each box plot contains 48 replicates of the experimental cond ition. Activity 
scores are calculated for each replicate using the logistic regression model 
described in Chapter 4. Negative represents the NFAT translocation phenotype 
at time 0 min. Positive represents the NFAT translocation phenotype after 20 
min. The Y-axis Activity Score is a percentile from 0 to 100 t h .  Image from 
(Wang & Ehrlich 2017). 
 
We used PMA/ionomycin as a control to CD3/CD28 activation to induce maximal 
NFAT translocation for a duration of 20 min in primary T cells. The negative control 
was created by omitting PMA/ionomycin. The cells were imaged and processed 
using the automated statistical workflow. The top discriminating features are shown 
in Figure 5-9. These features were selected based on the maximum separation 
between all the cumulative distribution functions (CDFs) of the negative and 
  
91 
positive controls using the previously described mRMR approach. These features 
were used as the input to the activity score logistic regression model. The model 
was then applied to each sample. Each sample produces a single overall ‘activity 
score’ which is a linearly weighted combination of the feature means and their 
corresponding coefficients (Figure 4-8). Activity scores are represented by 
cumulative box plots shown in Figure 5-10.  
 Figure 5-8 shows the 2-D fluorescent images of each NFAT sample. It was 
observed that the NFAT translocation phenotype was qualitatively stronger in 
primary T cells. The negative NFAT phenotype showed a clear boundary between 
cytoplasmic NFAT and nuclear PI, indicating a lack of translocation. The positive 
NFAT phenotype showed the opposite, much more overlap between NFAT and 
nuclear PI fluorescence. 
We evaluated the strength of the NFAT translocation readout using standard 
assay quality control metrics, the strictly standardized mean difference (SSMD) and 
Z’ were calculated for each induction method. Comparing Z’ and SSMD values allows 
us to analyze the high throughput capabilities of our technology. For the 
PMA/Ionomycin induction (Figure 5-10 Left), the Z’ = -0.39 and the SSMD = 2.92. 
While these numbers are not strong enough for a large scale primary screen, an 
SSMD of 3 is still acceptable for assays with weak positive controls (Bray & 
Carpenter 2004). As mentioned in Chapter 3.1.2, most of our variance comes from 
reproducible differences between parallel lanes — primarily optical aberrations 
across the scan field. We redid the analysis but modeled each lane individually. By 
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treating each lane separately, we remove any effects to lane-to-lane variance. The 
results are present in Figure 5-11. We achieved an average Z’ of 0.55 and SSMD = 
12.98, which is very reasonable for a high throughput primary screen. 
 
Figure 5-11. Z’ and SSMD values for both PMA/Ionomycin and CD3/CD28 induction of NFAT 
translocation in primary cells. 
The first row contains the Z’ and SSMD values calculated by using the entire 
pooled data set across all eight lanes of the microfluidic device without lane -
to-lane variability removed. The next 8 rows show statistics from each 
individual lane, with controls calculated for each individual lane to reduce the 
systematic variability between lanes from optical aberrations. The mean and 
standard deviation (SD) are calculated for all eight lanes to summarize the 
distribution of Z’ and SSMD values.  Table from (Wang & Ehrlich 2017). 
 
At the onset, we expected that the more physiological approach using standard 
CD3/CD28 antibodies would trigger a weaker NFAT translocation phenotype. This is 
because compared to ionomycin, which directly activates calcium channels and 
calcineurin, CD3 ligation is an indirect T cell activation method. Anti-CD3 does not 
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directly bind to the hypervariable region of the TCR and as a result, should be a 
weaker NFAT induction. Surprisingly, the separation between the positive and 
negative controls was greater using CD3/CD28 induction (Figure 5-10 Right). 
Across all lanes, the Z’ = 0.03 and SSMD = 4.28. After removing the lane-to-lane 
variance, the separation is much more pronounced. The average Z’ = 0.77 and SSMD 
= 22.44 (Figure 5-11), which indicates a very high separation between positive and 
negative controls with the CD3/CD28. These numbers are more than acceptable for 
a high throughput primary screen. 
 
 
5.6 Immune checkpoint anergy assay 
The experiments discussed up to this point demonstrate the ability of our 
technology to detect translocation phenotypes of a critical transcription factor 
(NFAT) during primary T cell activation. The next step was to investigate the 
immune response of immunotherapy drugs. We needed to establish a method to 
generate both healthy and immuno-compromised T cells. By obtaining both a 
population of healthy and immuno-compromised cells, we could then determine the 
relative drug response from immune checkpoint blockade. 
Because we wanted to study anti-PD-1 drug responses, we started by using 
PD-L1 to create an anergic population of T cells. When PD-L1 binds to the PD-1 
receptor, it triggers a cascade of signaling events that inhibits proximal TCR 
signaling molecules and leads to anergy (Francisco et al. 2010). Blocking the PD-
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L1:PD-1 binding event should prevent anergy, or at least recover the cells from 
anergy. 
5.6.1 PD-1 receptor expression (Primed population) 
In order to study the immune checkpoint pathway, one first needs the PD-1 
receptor. The PD-1 surface receptor is not natively expressed on resting PBMCs. In 
order for healthy peripheral T cells to express PD-1, priming is necessary. This 
involves activating the T cells with CD3 to simulate an antigen binding event and 
initial T cell activation. Purified naïve primary T cells are introduced to a pre-coated 
petri dish with immobilized anti-CD3 (OKT3 clone, 5 µg/mL). Cells are incubated in 
the petri dish for 24 hours at 37˚C. After incubation, cells are aspirated, washed and 
rested in a separate petri dish with C10 media for 72 hours. Creation of the primed 
population is summarized in Figure 5-14A. PD-1 receptor staining confirmed 
successful PD-1 expression (data not shown).  
After priming the cells, we also had to confirm that NFAT translocation was 
still a viable phenotype. It was important to repeat NFAT translocation in primed T 
cells since it is possible that the pathway is compromised or altered. Previous NFAT 
translocation experiments were conducted with naïve T cells directly purified from 
peripheral blood. After priming the T cells and resting for 72 hours, the cells were 
then removed and secondary TCR activation is applied. After 3 days rest, cells were 
removed from the incubator and placed on ice as before. For the positive control, a 
two-step TCR crosslinking was used, 5 µg/mL mouse anti-CD3 OKT3 (eBioscience 
  
95 
#16-0037) and 2.5 µg/mL mouse anti-CD28 (eBioscience #16-0289) were added 
and incubated with the chilled cells for 30 min on ice. Negative controls used 
unlabeled mouse IgG isotype control in place of primary antibodies. Goat anti-
mouse IgG (20 µg/mL, Invitrogen #A16074) was added to both controls and 
allowed to crosslink for another 30 min on ice. The positive control sample was 
placed in a 37˚C water bath for 20 min to induce translocation of NFAT and fixed 
with the same protocols. For the primary antibody, rabbit anti-NFAT1 (CST #4389, 
2 µg/mL) was added and incubated overnight at 4˚C. Then, secondary anti-rabbit 
Alexa 488 (Invitrogen #A11008, 10 µg/mL), 1:100 PI, and 20 µg/mL of RNase A 
were added to the mix and incubated for 30 min at 37˚C. Cells are prepared in flow 
buffer and imaged with the PMC. Activity scores are generated as previously 
described, a single set of coefficients is generated from a small set of positive and 
negative controls. The results and relevant coefficients are shown in Figure 5-12. 
These coefficients are then applied to every sample, 8 replicates from the positive 
control and 8 replicates from the negative control. Activity scores are displayed as 
boxplots. 
Features are recalculated for the activity score regression model as the 
negative and positive controls are different from standard unprimed NFAT or NF-kB 
translocation. Both the Z’ and SSMD (2.56) confirmed a high degree of separation for 
NFAT translocation. This indicates that the NFAT translocation pathway is not 
compromised in primed cells and maintains a strong spatial phenotype for the PMC 
readout. 
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Figure 5-12. Drug activity score box plot for NFAT translocation in primed T cells. 
Activity scores (relative %) for NFAT translocation for the primed T cell 
population. The feature coefficients from the activity score regression model is 
shown on the right. Each box plot contains 8 replicates. (Neg.) represents the 
phenotype of resting cells at 0 min. (Pos.) represents the same cells after 20 
min induction of NFAT translocation.  Red diamond represents the mean, line 
represents median. SSMD between the negative and positive samples is 2.56 
which is reasonable for a weak control .  
 
5.6.2 PD-L1 induction of anergy 
After confirming the healthy primed population, the next step was to generate a 
population of immuno-compromised cells aka the anergic population. Similar to the 
primed population, cells were incubated in a pre-coated petri dish with immobilized 
anti-CD3. However, in this case, chimeric PD-L1-Fc (Biolegend #762504, 5 µg/mL) 
is also immobilized alongside the anti-CD3 (5 µg/mL). Cells are activated and 
stained identical to the primed population in 5.6.2. After incubation with anti-CD3 
and PD-L1-Fc, the T cells are removed and rested for 72 hours. After 3 days rest, 
cells were removed from the incubator and placed on ice as before. For the positive 
control, a two-step TCR crosslinking was used, 5 µg/mL mouse anti-CD3 OKT3 
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(eBioscience #16-0037) and 2.5 µg/mL mouse anti-CD28 (eBioscience #16-0289) 
were added and incubated with the chilled cells for 30 min on ice. Negative controls 
used unlabeled mouse IgG isotype control in place of primary antibodies. Goat anti-
mouse IgG (20 µg/mL, Invitrogen #A16074) was added to both controls and 
allowed to crosslink for another 30 min on ice. The positive control sample was 
placed in a 37˚C water bath for 20 min to induce translocation of NFAT and fixed 
with the same protocols. For the primary antibody, rabbit anti-NFAT1 (CST #4389, 
2 µg/mL) was added and incubated overnight at 4˚C. Then, secondary anti-rabbit 
Alexa 488 (Invitrogen #A11008, 10 µg/mL), 1:100 PI, and 20 µg/mL of RNase A 
were added to the mix and incubated for 30 min at 37˚C. Cells are prepared in flow 
buffer and imaged with the PMC. Cells are imaged in the PMC and activity scores are 
calculated for each sample. 
For the anergic population, the activity score model used the same 
coefficients generated from the primed population. Since the resulting phenotype is 
based on similar methods, there is no need to generate a new regression model. 
Using the same regression model for both primed and anergic populations allows 
for comparison of relative NFAT translocation between the two populations. The 
feature selection algorithm is based on the original positive and negative control 
phenotypes, and is not biased towards any other spatial phenotypes or sample 
conditions. The addition of PD-L1 in the anergic population should bind to PD-1 
receptors and should trigger the immune checkpoint pathway. These T cells should 
have a functional immune state that resembles anergy when compared to the 
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activity score NFAT translocation of the primed population. Results are shown in 
Figure 5-13. 
                             
 
Figure 5-13. Drug activity scores for NFAT translocation in both primed T cells and anergic 
T cells. 
The two bars on the left represent the NFAT translocation response from 
healthy primed cells (N = 24 each bar). A strong change in phenotype is 
depicted by the large shift in activity score (normalized to percent activation). 
Each population is measured at 0 min and 20 min during the NFAT drug 
response. Bars on the right represent  the NFAT translocation response from 
anergic cells induced with immobilized PD-L1 (N = 24 each). The lack of 
separation indicates minimal changes NFAT translocation phenotype. *, p < 
0.01. Error bars indicate standard error.  
 
Anergy is a difficult phenotype to detect functionally as it is a hypo-responsive 
immune state. Anergy results in the lack of an immune response, signaling pathways 
such as NFAT/NF-kB are inhibited by the activation of the immune checkpoint 
pathway. Thus, we needed both primed and anergic T cell populations to measure 
relative NFAT drug responses.  
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Figure 5-13 (Anergic) showed that our artificially induced population had 
insignificant phenotypic changes in NFAT translocation, as indicated by the activity 
score readout. The results from this experiment provided evidence for the 
hypothesis that functional immune response is correlated to long term proliferation 
status. The healthy cell population (Primed) demonstrated a significantly strong 
NFAT translocation response. A paired student t-Test was applied at α = 0.01 to 
determine significance. Further validation studies are still needed. Verifying with 
cytokine or cell cycle analysis would help strengthen the hypothesis that NFAT 
translocation dynamics reflect proliferation status. We repeated the experiment but 
titrated PD-L1-Fc concentration down to 1 µg/mL. After reducing the PD-L1-Fc 
concentration, the NFAT translocation phenotype became stronger (data not 
shown). The results from these experiments provide evidence that T cell activation 
is correlated to long term proliferation status, as is consistent with the literature 
(Blackman et al. 1991; Riley 2009). 
5.6.3 Drug response relative to Primed and Anergic populations 
Now that we have a primed population (healthy cells, positive control) and an 
anergic population (unresponsive cells, negative control), we began testing the 
relative drug responses with respect to both controls. A diagram of the three 
populations is shown in Figure 5-14. This provides the overall structure of the 
immunotherapy assay. 
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Figure 5-14. Overview of immunotherapy assay setup with primed, anergy, and drug 
populations. 
The creation of each population A, B, and C is described in the methods. The 
first two populations, primed and anergic, will be used as the positive and 
negative controls, respectively. A successful drug candidate  (C) should recover 
the cells to resemble healthy cells again (A). Unsuccessful drug candidates will 
result in a phenotype that is still anergic (B) . 
 
The premise of the assay design was as follows: We first established both positive 
(primed) and negative (anergic) control populations so we could measure the 
maximum and minimal NFAT translocation response. These two populations were 
generated exactly as described in the previous two sections. For the third ‘drug 
population, various drugs were added to the population of anergic cells. In this way, 
one can measure the drug response relative to those two initial control populations 
(Figure 5-14C).  
A 
B 
C 
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Similar to the methods from the anergic population, the cells were incubated 
with immobilized CD3 and PD-L1-Fc. During this time, drug candidates were added 
simultaneously to the petri dish. Those drug candidates included: anti-PD-1 (J116 
clone, 5 µg/mL), anti-CD28 (CD28.2 clone, 2.5 µg/mL), or IL-2 (eBioscience #14-8-
29, 500 ng/mL). For anti-CD28, the antibody was immobilized alongside PD-L1-Fc 
and anti-CD3. For IL-2, the cytokine was added during the 24-hour induction period 
and refreshed during the 72-hour resting period. Both IL-2 and anti-CD28 
candidates have shown to recover/prevent T cells from entering anergy (Shen et al. 
2016; Bennett et al. 2003). For anti-PD-1, the antibody drug was added in soluble 
form at the beginning of the 24 hours incubation. This particular clone J116 has 
been confirmed to inhibit the PD-1 signaling pathway but does not block the binding 
of PD-L1 (Dong et al. 2002). 
All cells were imaged in the PMC after the 72-hour resting period and 
analyzed in the PMC. The selected features and regression model are identical from 
the primed population. The activity score still represents the relative translocation 
response in comparison to the primed population. For a drug candidate to be 
determined to have a significant drug response, the NFAT translocation response 
should resemble a healthy (positive control) population of T cells. Successful drug 
candidates should either recover immuno-compromised cells from anergy, or 
prevent anergy from developing in the first place. 
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5.6.4 Results from IL-2 and anti-CD28 
 
Figure 5-15. NFAT translocation activity scores from IL-2 and anti-CD28 drug responses. 
NFAT translocation response from the control drug candidates IL -2 and anti-
CD28, relative to the original primed and anergic populations (N = 25). 
Significant changes between 0 min and 20 min phenotypes are observed in both 
IL-2 and anti-CD28 drug responses. Activity scores are normalized to percent 
activation. The first two columns (Primed/Anergic) serve as positive/negative 
controls to analyze the strength of NFAT translocation respectively. *,  p < 0.01. 
Error bars indicate standard error.  
 
                      
Ligands to CD28 act as direct competitors to the PD-1 receptor and can override 
inhibitory effects from PD-1 ligation. This response is concentration dependent. 
Large concentrations of IL-2 can also bypass the PD-1 pathway and suppress 
inhibitory signaling cascades even after successful PD-1 ligation. PD-1 binding can 
suppress IL-2 production resulting in T cell anergy, and vice versa, increasing IL-2 
can prevent induction of anergy (Chikuma et al. 2009).  
Looking at Figure 5-15, it can be seen that the NFAT activity score responses 
from these two drug candidates (IL-2 and anti-CD28) were significantly higher than 
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the anergic translocation response. However, the NFAT translocation was not as 
strongly separating as the primed population. This could be a side effect of anergic 
recovery. Full recovery of the NFAT signaling pathway may require a longer time 
frame. Although cells rapidly recover from anergy due to IL-2 after a couple days or 
less, it is typically measured through cell cycle counting or cytokine analysis. Direct 
effect on the kinetics and strength of transcription factor localization is unknown 
during anergic recovery. Ligation of the PD-1 receptor leads to an immediate down 
regulation in TCR expression that recovers slowly over the course of 3 days 
(Karwacz et al. 2011). Although we rest the cells for 3 days after induction, the 
NFAT and TCR signaling pathways may still be compromised. Further studies are 
needed to fully understand the effects on NFAT translocation dynamics during PD-1 
drug responses.  
We did observe that cells introduced to anti-CD28 and IL-2 were 
proliferating normally, despite the lower NFAT translocation activity score. Anergic 
cells are ‘sickly’ and have lower cell counts than primed cells. It was confirmed that 
cells with IL-2 and anti-CD28 had higher cell counts and media absorption (Phenol 
Red shifts to the yellow spectrum after cells secrete waste products).  The data 
suggests that the addition of anti-CD28 and IL-2 were partially successful in 
recovering from PD-L1 induced anergy. 
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5.6.5 Results from anti-PD-1 
 
Figure 5-16. NFAT translocation scores from anti-PD-1 drug response. 
NFAT translocation response from testing the immune checkpoint blo ckade 
antibody drug anti-PD-1 (N = 24). No significant shifts in NFAT translocation 
phenotype was detected after introducing PD-1 blockade. Activity scores from 
the anti-PD-1 population resemble the  0 min and 20 min phenotypes from the 
negative population (Anergic), indicating a lack of drug response activity. *, p < 
0.01. Error bars indicate standard error.  
 
In theory, the introduction of an antagonistic anti-PD-1 drug (clone J116) should 
block inhibitory effects from PD-1 ligation. Many research groups have applied 
various drug candidates to suppress or block the PD-1:PD-L1 interaction and have 
successfully recovered/prevented cells from anergy (Wong et al. 2007; Okazaki & 
Honjo 2007; Podojil & Miller 2009). In vitro methods used to induce PD-1 related 
anergy traditionally involve transfecting the PD-L1 ligand into dendritic cells or cell 
lines. This method is a physiological method of presenting an antigen, such as PD-L1, 
to T cells, but was not practical in our laboratory. We decided on using immobilized 
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PD-L1-Fc on petri dishes which has not been attempted previously. There has been 
one study that used a peptide pool and anti-PD-1 blocking antibodies in vitro in petri 
dishes that was very similar to our approach (Grenga et al. 2016). Further 
discussion with researchers from Arlene Sharpe’s group was encouraging using 
immobilized PD-L1-Fc but were primarily based on bead immobilization. Due to the 
difficultly of immobilizing proteins on beads, plastic petri dishes were decided as a 
compromise. 
 Looking at Figure 5-16, the data suggests that the introduction of anti-PD-1 
did not prevent anergy and did not recover cells back to a healthy proliferation 
state. NFAT translocation from anti-PD-1 treated cells was undetectable, similar to 
the drug response from the anergic population. Although our specific PD-1 antibody 
does not directly bind to the active site on the PD-1 receptor to block ligation, the 
antibody works by preventing downstream signaling from PD-1 after binding.  
We attempted many different methods to replicate the results from clinical 
trials and literature. We varied incubation periods from 24 hours to 48 hours with 
the drug candidate, multiplexed with a PD-L1 blocking antibody, titrated multiple 
concentrations up to 20 µg/mL, tested both soluble and immobilized antibody 
induction, changed the length of the resting period after drug incubation, and tried 
an alternate drug induction method. The alternate induction method involved 
priming the cells with immobilized anti-CD3 first for 24 hours. Then, the cells were 
transferred to a suspension tube with soluble anti-PD-1. After 30 min, the cells were 
transferred back to a petri dish with PD-L1-Fc for 12 hours. After probing with PD-
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L1-Fc, the cells are finally moved to a culture flask and rested. None of these 
modifications resulted in a significant or consistent NFAT translocation response. 
We did observe successful NFAT translocation in some experiments, but those 
results were deemed to be false positives due to human error or variance from low 
cell counts.  
We have been unable to find any previous reports in which immobilized PD-
L1-Fc was used as a means to recover cells from anergy in vitro. It is possible that 
the anergic state induced in this fashion is permanent, or requires a different 
sequence, or other factors available in vivo for recovery. Steric effects from the petri 
dish/cell interface may prevent the anti-PD-1 drug from blocking the PD-1 pathway. 
Another possible source of error is our choice of translocation readout. Most 
research groups measure anergic recovery using cytokine (IL-2, IFNγ) analysis or 
surface proliferation markers (CD25/CD69). It is possible that proliferation status 
was successfully recovered in our experiment from anti-PD-1 blockade, as would be 
measured by cytokines, but the NFAT translocation state was not restored. Since 
there is no literature on NFAT translocation strength during anergic recovery, more 
studies are needed to confirm that our negative result is a true biological result, and 
not due to failures in experimental design. 
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5.7 Direct adaptations from HCA 
5.7.1 Motivation 
It is important to compare our new 1-D imaging cytometry to the existing classical 
and established methods for drug screening and testing. There are existing 
standardized and well-established methods for drug screening. We adapted multiple 
quantitative cross checks to established methods. 
5.7.2 Dose response 
To test the ability of the PMC to measure dose response curves, NFAT translocation 
was measured using standard anti-CD3 TCR activation. Two-step TCR crosslinking 
was used, varying concentrations (0 – 10 µg/mL) of anti-CD3 OKT3 (eBioscience 
#16-0037) and anti-CD28 (eBioscience #16-0289, CD28.2) were added and 
incubated with the chilled cells for 30 min on ice. CD28 antibody concentration was 
half the concentration of the corresponding anti-CD3 concentration. Negative 
controls used unlabeled mouse IgG isotype control in place of primary antibodies. 
Goat anti-mouse IgG (20 µg/mL, Invitrogen #A16074) was added and allowed to 
crosslink for another 30 min on ice. All samples were placed in a 37˚C water bath for 
20 min to induce translocation of NFAT and fixed with the same protocols.  
Results are presented in Figure 5-17. The NFAT activity score on the y-axis 
represents the fractional percent translocation of NFAT. The EC50 point for 
CD3/CD28 activation is indicated with a dashed line at 0.3 µg/mL which is 
consistent with the literature (Tomkowicz et al. 2015). 
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Figure 5-17. EC50 dose response curve for NFAT translocation using anti-CD3/CD28 TCR 
activation. 
NFAT translocation was induced in primary T cells with anti-CD3/CD28 
antibodies. Concentration of antibody was varied acros s 10-fold dilutions. EC50 
point was measured to be around 0.3 µg/mL. Each point is the mean of 9 
replicates (N=9). Error bars represent standard error (SEM). Y-axis represents 
relative NFAT translocation to high/low controls.  
 
As a second quantitative test, an IC50 dose response assay was preformed using 
Cyclosporin A (CsA). Calcineurin is responsible for the de-phosphorylation of the 
NFAT subsequent nuclear translocation. Since CsA directly binds to calcineurin and 
inhibits substrate binding, adding increasing concentrations of CsA should lead to 
lower levels of IL-2 activity (Murphy & Hughes 2002; Leitner et al. 2011). Although 
the PMC readout uses NFAT translocation as its readout, there should be a strong 
correlation between NFAT translocation and IL-2 activity. 
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The IC50 is reported to be in the range of 1 µg/mL to 10 µg/mL in the 
presence of costimulatory CD28 activation (Leitner et al. 2011; Murphy & Hughes 
2002). With ionomycin induction of NFAT, the IC50 of CsA is reported to be in the 
range of 0.1 µg/mL (Maguire et al. 2013). The immunosuppressive effect of CsA is 
much less effective with CD28 co-stimulated T cells (Leitner et al. 2011). 
Cells were incubated with varying concentrations of CsA (0.005–500 µg/mL 
with 10-fold dilutions) for 30 min at 37˚C. After incubation with CsA, cells were 
activated as described previously (CD3/CD28 antibodies) and stained for NFAT 
translocation. Two-step TCR crosslinking was used, 5 µg/mL of anti-CD3 OKT3 
(eBioscience #16-0037) and 2.5 µg/mL anti-CD28 (eBioscience #16-0289, CD28.2) 
were added and incubated with the chilled cells for 30 min on ice. Negative controls 
used unlabeled mouse IgG isotype control in place of primary antibodies. Goat anti-
mouse IgG (20 µg/mL, Invitrogen #A16074) was added and allowed to crosslink for 
another 30 min on ice. All samples were placed in a 37˚C water bath for 20 min to 
induce translocation of NFAT and fixed with the same protocols.  
Results are shown in Figure 5-18. The IC50 point was measured to be around 
0.1 µg/mL. This concentration is an order of magnitude off compared to results from 
CD28 co-stimulated cells (Leitner et al. 2011), but is almost identical to the IC50 
point obtained using ionomycin induction (Maguire et al. 2013). We suspected the 
discrepancy was due to differences in readout method and NFAT induction. The 
strength of NFAT translocation is loosely correlated to the strength of IL-2 
upregulation. Each readout method has different mechanisms and dynamics. IL-2 
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and cell count measurements are bulk measurements, which may not be 
representative of the individual characteristics of each cell, which our method 
measures. Another reason for the discrepancy could be that the immunosuppressive 
effect of CsA is more potent in primary cells, so less CsA is needed. More research 
needs to be done to correlate the immediate dynamics of NFAT translocation with 
long term proliferation.  
 
Figure 5-18. Cyclosporin A (CsA) IC50 inhibition dose response curve for NFAT 
translocation. 
NFAT translocation was measured in primary T cells.  Cells were induced with 
identical CD3/CD28 concentrations but were pre -incubated with varying 
concentrations of CsA at 10-fold dilutions. The IC50 point was measured to be 
around 0.1 µg/mL. Each point is the mean of 9 replicates (N=9). Error bars 
represent SEM. Y-axis represents relative NFAT translocation to high/low 
controls. 
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5.7.3 Temporal response 
One of the initial goals of this work was to test the ability of the PMC to measure 
transient phenotypes and kinetics within T cells with high temporal resolution. Both 
NF-kB and NFAT were measured multiple time intervals. Cells were labeled with 
primary antibodies against CD3 (eBioscience #14-0037, OKT3 clone, 5 µg/mL) and 
CD28 (eBioscience #16-0289, CD28.2 clone, 2.5 µg/mL), on ice; secondary 
antibodies are added to crosslink primary antibodies (Invitrogen anti-mouse IgG 
#A16074, 20 µg/mL). Both NFAT and NF-kB translocation was induced by 
submerging samples in 37˚C water bath. Cells were removed at 15 min intervals for 
a total of 60 min as indicated by the graphs. NFAT and NF-kB were stained 
separately and imaged in the PMC. Temporal response curves were constructed for 
each transcription factor. As seen in Figure 5-19, the PMC was able to measure 
temporal dynamics during both NF-kB and NFAT translocation. 
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Figure 5-19.  NFAT and NF-kB translocation activity scores from 0–60 min. 
A) NFAT translocation was induced with PMA/ionomycin (10 µg/mL/10 mM) in 
a water bath. Samples were taken out and fixed at 15 min intervals to measure 
the temporal changes in spatial localization over time. Each box plot repr esents 
8 replicates (N=8). B) NF-kB translocation was induced with TNFa (500 
ng/mL). Samples were taken out and fixed at 15 min intervals. Each box plot 
represents 8 replicates (N=8).  
 
As mentioned in section 5.5, NF-kB is a very weakly translocating response and 
cannot be visually confirmed using 2-D microscopy. Because regression modeling 
A) 
B) 
  
113 
attempts to maximize the distance between positive and negative phenotypes, even 
subtle weak phenotypes will be detected by the PMC. We were still able to observe 
noticeable changes over time in the NF-kB phenotype (Figure 5-19B). The rate of 
translocation is consistent with kinetic rates in the literature, around maximal 
translocation around 45 min (Molitor et al. 1990). However, individual variance 
across replicates for each time point is also much higher for NF-kB. This is a sign 
that the phenotype is much weaker for NF-kB and the algorithm is not as highly 
separating. 
On the other hand, the temporal curve for NFAT translocation produced 
much larger separations between temporal phenotypes (Figure 5-19A). However, as 
evident from the data, NFAT translocation is much more rapid and binary in its 
translocation response. The rate of translocation is consistent with the literature, 
maximal NFAT translocation occurs around 20 to 30 min (Torgerson et al. 1998). 
To further investigate the rapid translocation response, we looked NFAT 
translocation with higher temporal resolution. Cells were removed at 1 min 
intervals instead of 15 min intervals. Intermediate phenotypes were detected and 
confirmed (Figure 5-20).  
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Figure 5-20. Temporal response curves for NFAT translocation from 0–8 min. 
NFAT translocation was induced with PMA/ionomycin using the same methods 
in Figure 5-19. However, samples were taken out and fixed at 1 min intervals 
for a total of 8 min. Each box plot represents 8 replicates (N=8).  
 
The data presented above show the ability of the PMC to measure intermediate 
phenotypes. The intermediate phenotypes are consistent with the standard 
temporal kinetics as described in the literature. Looking at subtle spatial 
phenotypes as a function of time is similar to studying kinetics of signaling 
pathways. This kind of data can be very useful in understanding the true 
mechanisms of drug interactions, and how drugs would affect the kinetic signatures 
of signaling pathways within T cells. 
Unfortunately, it is impractical to measure full kinetic curves for each 
experiment. Most of our assays use a single time point at 20–40 min to determine 
  
115 
the strength of the translocation response. Although they are of considerable 
scientific interest, at the moment these kinetic studies are not practical as a new 
approach for high-content screening. Differences in slope, time constant, magnitude 
of response, or duration could in the future elucidate new or subtle differences in 
the strength of a translocation response. This would help understand the 
mechanism of actions for new drugs, and could become practical with a professional 
level of optimization of our PMC technology, even with high throughput 
applications. More research would be needed to understand how these kinetic 
signatures correspond to mechanisms of drug action. 
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Chapter 6 - Conclusions 
 
6.1 Summary of Aims 
One of the main advantages to using 1-D cytometry as a screening tool is the speed 
and objectiveness of decision making.  Our technology is well-suited for rapid assay 
development due to its automated and unsupervised statistical workflow. Combined 
with the data efficiency of 1-D imaging and low sample consumption, high 
throughput high content cytometric analysis is possible with primary T cells. 
Although protein localization is not resolved to the accuracy of 2-D microscopy, our 
activity score model infers relative spatial and temporal cellular phenotypes with 
nearly the same accuracy and much higher data efficiency. Overall, the goal of this 
work was to improve and develop 1-D cytometry as a viable method for high 
throughput screening. In addition, we developed primary T cell assays using the 
PMC technology to study the drug responses by probing the immune checkpoint 
pathway. 
 In aim 1, improvements to the instrumentation and reliability of the PMC 
signal were conducted. Optical sensitivity and SNR were investigated and optimized 
through sample digitalization, optical filters, and better mechanical alignment. Lane-
to-lane variance was minimized with algorithmic normalization and by using better 
control samples. Microfluidics and operational protocols were modeled and 
optimized for continuous high throughput operation. This is key for screening 
applications that require assay stability and speed in both imaging and analysis. 
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Data storage and sample volume requirements were both minimized to highlight the 
efficiency possible with the PMC platform. 
 In aim 2, we designed a hands-off method of automated statistical analysis of 
1-D imaging data. Current 2-D HCS requires highly trained expert operators to 
develop assays. Often, this requires subjective gating steps and ‘intuitive’ decisions 
to determine physiological phenotypes. Our method was focused on unbiased assay 
development. We designed automated algorithms to isolate the most statistically 
significant features obtained from our 1-D images. We used the most relevant 
features to build an ‘sample-blind’ regression model which outputs a single activity 
score without any expert input (except for labeling of positive and negative 
controls). The activity score model allows users to quickly measure drug responses 
during a high throughput screening assay.  
 In aim 3, we applied the improved PMC hardware and statistical analysis to 
developing an immunotherapy assay using primary T cells. NFAT and NF-kB 
translocation were studied as possible functional readouts for determining the state 
of internal signaling pathways. NFAT was determined to be the more informative 
and reliable readout. The first step was to validate the ability of the PMC to 
differentiate between subtle spatial phenotypes within T cells. After successful 
implementation of the algorithms, the next step was to use NFAT translocation to 
measure the functional state of the immune checkpoint pathway. Our main goal was 
to correlate short-term T cell activation dynamics with long term proliferation to 
validate our approach. We made significant progress in constructing an assay using 
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primed and anergic cell populations as positive and negative controls. Drug 
responses from IL-2, CD28, anti-PD-1, and anti-PD-L1 were studied. By investigating 
the ability of drug candidates to prevent or recover cells from anergy, we hoped to 
prove the PMC platform for immunotherapy drug screening. IL-2 and CD28 did 
partially recover cells from anergy and served as a control for the immune 
checkpoint blockade antibody drugs. Unfortunately, we could not achieve a 
consistent recovery from anergy using anti-PD-1. Further work is needed to 
optimize experimental methods and validate with cytokine analysis. 
 
6.1.1 Future directions 
 
If resources permit, we would want to conduct an immunotherapy drug screen 
against a real and useful library of candidate compounds. Testing known drug 
candidates that have predictable drug responses is much different from a blind 
screening assay, where drug responses are unknown. It is possible that alternate 
phenotypes may occur from small molecule interactions, and it would be a good 
exercise to validate our ‘sample-blind’ approach. Ideally, we would use a library of 
mAbs or peptides that are presumed to interact with the PD-1 receptor as an agonist 
or antagonist. 
While the current throughput of our technology is sufficient for small 
screening assays, we project that our system can be expanded even further. Drug 
discovery applications may require hundreds of thousands or millions of 
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compounds. In previous publications, we were able to show our digitalization rates 
and signal-to-noise ratios are consistent with a throughput of ten 384-well plates 
per hour (McKenna et al. 2011). A more current ADC (analog-to-digital converter, 
Vertilon IQSP518) with a maximum 390 kHz digitalization rate will increase our 
current sampling rate by 8-fold. Combined with improved twin-device switching, as 
used in a previous DNA sequencing system (Aborn et al. 2005), we can eliminate 
nearly 100% of the refresh time of sample loading and microfluidic recycling. With 
the updated 96-lane chip design, the system should be able to image across all 
parallel channels every 25 seconds resulting in a throughput of ten 384-well plates 
every 17 minutes. Our statistical workflow can be applied at this speed for “on-the-
fly” continuous operation with minimal data buffering. This would allow screening 
of more than 350,000 compounds per day on a single instrument. This is an order of 
magnitude improvement over the current throughput of present commercial 2-D 
HCS instruments. 
The assay we presented in this work uses a dual color 1-D image to detect 
localization of a single biomarker (NFAT). However, during the cellular processes of 
the immune checkpoint pathway, many parallel and downstream signaling events 
also occur. We would like to multiplex our readout with multiple readouts of 
different signaling markers. Signaling proteins such as ERK, STAT, AP-1, and AKT 
have separate localization dynamics which are downstream of T cell activation and 
the immune checkpoint pathway. 
We envisioned the PMC for use with clinical applications as well. For 
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personalized medicine, it would be credible to conduct a pilot test using actual 
patient samples with immuno-compromised T cells.  Predictably, there is an 
incentive to study the drug response of patient samples to immunotherapy drugs. As 
mentioned in the background chapter, some immunotherapies are only effective in 
certain patients with specific mutations. Peripheral T cells have also been shown to 
reflect the tumor state from a patient. The immunotherapy assay we designed could 
easily be modified to act as an alternative preliminary screen to predict patient drug 
response. A method to directly test ex vivo functional drug responses could be useful 
in clinical applications. Since primary cell samples from patients would be limited, 
the PMC’s volume efficiency allows assays to be performed even in clinical settings. 
6.1.2 Conclusions 
Our technology occupies a middle ground between classical flow cytometry and 2-D 
imaging. The results presented place the PMC platform as an unbiased objective 
approach to drug screening. The unbiased approach is extremely important to 
eliminate subjective manual gating approaches of current cytometric methods. 
Having an automated statistical analysis reduces the need for trained expert 
operators that rely on intuition and experience. These methods are prone to errors 
in human judgement and confirmation bias. Our automated unsupervised approach 
also vastly reduces the time needed for assay development.  
High throughput operation is optimized and scalable with our technology. 
This is especially important in drug discovery applications that screen for thousands 
  
121 
or millions of drug candidates. Using human primary T cells in large-scale screening 
assays has been previously impossible due to the limited volume requirements of 
primary cell samples. Adoption of physiological relevant assays in drug discovery 
will only improve the reliability and accuracy. Our low volume and efficient 
handling of primary cell samples allows for thousands of experimental conditions 
from a single donor. In addition, our efficient and rapid analysis of human primary T 
cells has great potential for personalized medicine and clinical studies. 
We should add that anergy has also been extremely difficult to study to this 
point due to its inert nature. Although impractical for high-throughput, the ability to 
probe drug interactions on anergic cells will help study the biological mechanisms of 
immune checkpoint blockade drugs and also lead to advancements in better 
screening assays. This is important as there is a huge trend in developing antibody 
drugs that target the immune checkpoint pathway, many of which are poorly 
characterized and understood. There also exists the potential for personalized 
medicine in probing anergic cells taken from patients. Many patients are tested for 
genetic markers that determine eligibility for a drug study. Testing the efficacy of 
drugs on patient blood samples could be a useful non-invasive method to measure 
drug response. 
The significant points presented here highlight the advantages of 1-D 
imaging. We demonstrate that 1-D imaging provides many new ways to characterize 
and study primary T cells, and encourages future research directions in both high-
throughput drug screening and anergic T cell analysis.  
  
122 
APPENDIX 
 
 
Figure 1.  Full layout and wiring/connecting diagram for integra ted PMC 
prototype with automated fluidics and robotic pipettors.  Following pages 
contain individual layouts for each numbered subsection. Custom written 
programs controlled the drivers and microchip Input/Output. Additional 
controller software used custom protocols to run assays with minimal operator 
interaction.  
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Figure 2.  Custom conditioning circuit. Low pass op-amps filters are used to 
amplify and modulate a triangle wave. Integrator adds a DC voltage to the 
wave. Resistance and capacitors are chosen to filter out 60 Hz noise.  
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Figure 3. Arduino circuit to control PMT gains through a serial port.  AD5206 
is a 6 channel potentiometer to control resistance on PMT.  Red lines indicates 
wiring connections between inputs/outputs.  
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Figure 4.  AutoCAD design for a 96-well microfluidic chip. 96 parallel wells 
would allow for even higher throughput.  Input wells align with a standard 96-
well plate.  
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Figure 5.  Video still frame of beads flowing through chip. Velocity is calculated  
by tracking beads frame by frame. Individual bead data is shown in Figure 6.  
 
Figure 6. Individual bead tracking velocities. 
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xpos Position for well location (x-axis) 
linenum Tracking time (y axis) 
r_noise_std_pmt1 Noise 
r_maxpeak_pmt1 Peak Intensity 
r_snr_pmt1  
r_smoothed_std_pmt1 Smoothness 
r_left_fwhm_pmt1 Width 
r_right_fwhm_pmt1  
r_lr_fwhm_pmt1  
r_ref_left_fwhm_pmt1  
r_ref_right_fwhm_pmt1  
r_ref_lr_fwhm_pmt1  
r_fwhm_pmt1  
r_fw75m_pmt1  
r_fw25m_pmt1  
r_fw25m_fw75m_pmt1  
r_left_top_slope_pmt1 Slope 
r_left_mid_slope_pmt1  
r_left_bot_slope_pmt1  
r_left_avg_slope_pmt1  
r_right_top_slope_pmt1  
r_right_mid_slope_pmt1  
r_right_bot_slope_pmt1  
r_right_avg_slope_pmt1  
r_lr_slope_pmt1  
r_left_area_pmt1 Area 
r_right_area_pmt1  
r_lr_area_pmt1  
r_ref_left_area_pmt1  
r_ref_right_area_pmt1  
r_ref_lr_area_pmt1  
r_top_area_pmt1  
r_bot_area_pmt1  
r_bt_area_pmt1  
r_total_area_pmt1  
r_left_peri_pmt1 Perimeter 
r_right_peri_pmt1  
r_lr_peri_pmt1  
r_ref_left_peri_pmt1  
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r_ref_right_peri_pmt1  
r_ref_lr_peri_pmt1  
r_total_peri_pmt1  
r_roundness_pmt1 Perimeter/Area 
s_num_peak_pmt1 Repeat for Smoothed Curve 
s_center_pmt1  
s_left_fwhm_pmt1  
s_right_fwhm_pmt1  
s_lr_fwhm_pmt1  
s_ref_left_fwhm_pmt1  
s_ref_right_fwhm_pmt1  
s_ref_lr_fwhm_pmt1  
s_fwhm_pmt1  
s_fw75m_pmt1  
s_fw25m_pmt1  
s_fw25m_fw75m_pmt1  
s_left_top_slope_pmt1  
s_left_mid_slope_pmt1  
s_left_bot_slope_pmt1  
s_left_avg_slope_pmt1  
s_right_top_slope_pmt1  
s_right_mid_slope_pmt1  
s_right_bot_slope_pmt1  
s_right_avg_slope_pmt1  
s_lr_slope_pmt1  
s_left_area_pmt1  
s_right_area_pmt1  
s_lr_area_pmt1  
s_ref_left_area_pmt1  
s_ref_right_area_pmt1  
s_ref_lr_area_pmt1  
s_top_area_pmt1  
s_bot_area_pmt1  
s_bt_area_pmt1  
s_total_area_pmt1  
s_left_peri_pmt1  
s_right_peri_pmt1  
s_lr_peri_pmt1  
s_ref_left_peri_pmt1  
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s_ref_right_peri_pmt1  
s_ref_lr_peri_pmt1  
s_total_peri_pmt1  
s_roundness_pmt1  
s_left_cyto_area_pmt1  
s_right_cyto_area_pmt1  
s_lr_cyto_area_pmt1  
s_cyto_area_pmt1  
s_nuc_area_pmt1  
s_cytonuc_area_pmt1  
s_diff_cytonuc_area_pmt1  
n_left_fwhm_pmt1 Repeat for Normalized Curves 
n_right_fwhm_pmt1  
n_lr_fwhm_pmt1  
n_ref_left_fwhm_pmt1  
n_ref_right_fwhm_pmt1  
n_ref_lr_fwhm_pmt1  
n_fwhm_pmt1  
n_fw75m_pmt1  
n_fw25m_pmt1  
n_fw25_75m_pmt1  
n_left_top_slope_pmt1  
n_left_mid_slope_pmt1  
n_left_bot_slope_pmt1  
n_left_avg_slope_pmt1  
n_right_top_slope_pmt1  
n_right_mid_slope_pmt1  
n_right_bot_slope_pmt1  
n_right_avg_slope_pmt1  
n_lr_slope_pmt1  
n_left_area_pmt1  
n_right_area_pmt1  
n_lr_area_pmt1  
n_ref_left_area_pmt1  
n_ref_right_area_pmt1  
n_ref_lr_area_pmt1  
n_top_area_pmt1  
n_bot_area_pmt1  
n_bt_area_pmt1  
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n_total_area_pmt1  
n_left_peri_pmt1  
n_right_peri_pmt1  
n_lr_peri_pmt1  
n_ref_left_peri_pmt1  
n_ref_right_peri_pmt1  
n_ref_lr_peri_pmt1  
n_total_peri_pmt1  
n_roundness_pmt1  
n_left_cyto_area_pmt1 Segmentation into thirds, outer third 
n_right_cyto_area_pmt1  
n_lr_cyto_area_pmt1  
n_cyto_area_pmt1  
n_nuc_area_pmt1 Inner third 
n_cytonuc_area_pmt1  
n_diff_cytonuc_area_pmt1 Area difference between cyto/nuc 
g_sigma_pmt1 Gaussian fitted features 
g_fwhm_pmt1  
g_center_pmt1  
g_peak_pmt1  
g_R2_pmt1  
g_left_area_pmt1  
g_right_area_pmt1  
g_lr_area_pmt1  
g_total_area_pmt1  
g_left_peri_pmt1  
g_right_peri_pmt1  
g_lr_peri_pmt1  
g_total_peri_pmt1  
 
Figure 7.  Table of features for a single  PMT channel. This list is repeated for 
each color. For a 2-color assay, each feature is also compared between PMTs  
(not included). Caption: R = raw, S = smoothed, N = normalized, G = Gaussian 
fitted curve, lr = left/right, bt = bottom/top, ref = feature i s calculated using 
reference channel, 25 = 25% height from peak, 75% height from peak.  
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